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Chapter I 
INTRODUCTION 

1.1 General introduction 
1.1.1 Epidermal growth and differentiation 
The subject of investigation in this thesis is human epidermis in vivo. In the most general 
sense, the function of skin is to seperate the body from its environment; that is, to keep 
the inside in and the outside out This task is partly accomplished by the dermis 
("mechanical barrier"), melanocytes ("radiological barrier") and Langerhans cells 
("immunological barrier"), but the "chemical defence" is formed exclusively by 
keratinocytes. They make up three distinct, successive compartments: an innermost layer 
of dividing keratinocytes (stratum basale), an intermediate region of differentiating 
keratinocytes (stratum spinosum & stratum granulosum) and a superficial layer of 
comified envelopes (stratum comeum). It is this last layer which is the true barrier: almost 
totally impermeable to water, salts and micro-organisms, partly impermeable to chemicals 
and ultraviolet light and continuously renewed from the inside to compensate for natural 
wear and tear. Hence epidermal growth and differentiation are closely linked. Figure 1 
shows the histology of healthy human epidermis. 
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Fig.l D= dermis, E= epidermis, SB= str. basale, SC= str. corneum 
1.1.2 Epidermal growth in relation to cutaneous inflammation 
The physiological process of continuous epidermal renewal mentioned in paragraph 1.1.1 
can become pathologic in several ways, resulting in the richly scattered palette of 
dermatology. Almost all skin diseases, however, are characterized by variable degrees of 
disturbances in proliferation and differentiation only. Besides, proliferation and 
differentiation are nearly always related to inflammation, primarily or secondarily. These 
are the same processes that are involved in the response to a trauma. Removal of the 
stratum corneum by tape stripping, irradiation with UV-B, application of phorbol esters or 
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allergens: sooner or later this will be followed by hypeiproliferation, inflammation and 
altered differentiation. Hence a common pathway seems likely; an hypothetical schedule is 
given in Figure 2. 
For example, a somatic mutation will cause an "intrinsic error" in the biochemical 
processes controlling proliferation. The mutant cell will divide and divide without control 
and after a critical level the tumor will cause pressure and diminished bloodflow to its 
surrounding cells. This can be interpreted as a trauma, resulting in inflammation and 
disturbed differentiation of both the tumor and its environment. But in the monogenetic 
disorders of keratinization an "intrinsic error" dysregulates a specific part of the 
biochemical process controlling differentiation. As explained in paragraph 1.1.1, this will 
result in a decreased barrier function and hence any minor stimulus from outside may act 
as a trauma. Of course this will be followed by hyperproliferation and inflammation. In an 
experimental approach, it is also possible to induce inflammation "en sec". Five to fifty ng 
of LTB4 applied to the skin will cause an infiltrate of polymorphonuclear leucocytes. This 
"aggressive" micro-abcess will be very traumatizing for its normal neighbour cells, finally 
resulting in hyperproliferation and pathologic differentiation. 
In the common pathway described in Figure 2, protein kinase С (PKC) probably 
plays a role. In the epidermis, stimulation of the membrane-bound epidermal growth factor 
receptor (with intrinsic tyrosine kinase activity) by transforming growth factor α (an 
endogeneous cytokine) causes activation of phospholipase G This enzyme in tum causes 
the formation of diacylglycerol, which finally activates PKC.1 Activated PKC will then 1) 
induce proliferation, i.e. by phosphorylation (and activation) of transcription factors, and 2) 
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will initiate inflammation by phosphorylation (and hence inactivation) of lipocortin. The 
former leads to the production of ornithine decarboxylase,2 which is essential for new 
DNA synthesis, and the latter, via release of phospholipase A2, leads to the formation of 
leucotrienes and prostaglandins from arachidonic acid.3 Both are potent mediators of 
inflammation; prostaglandin Ej causes vasodilatation and leucotriene B4 attracts 
inflammatory cells such as polymorphonuclear leucocytes. Hence, in pathologic 
circumstances, epidermal growth and inflammation are closely linked, both at the clinical 
and biochemical levels. 
Fig.2 CP= common pathway, D= differentiation, 1= inflammation, 
P= proliferation, T= trauma 
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1.13 Psoriasis, a disorder of cutaneous inflammation and epidermal proliferation 
Psoriasis affects about 2% of the world's population and shows a polygenic pattern of 
inheritance. Oddly, the disease is precipitated by various non-genetic triggering factors, 
both internal and environmental, such as local trauma, stress, hormones, injections, drugs 
and hypocalcaemia. Sharply defined, thickened, red lesions may appear anywhere on the 
body, often beginning on the elbows or knees; these tend to grow slowly in size until 
much of the body surface is involved. Several less common variants exist, e.g. generalized 
pustular psoriasis, persistent palmoplantar pustulosis and acrodermatitis contìnua 
superativa; extracutaneous manifestations are found in the nails, the mucosal membranes 
and the joints. 
At the microscopical level, psoriasis is characterized by acanthosis and 
parakeratosis, absence of the granular layer, thinning of the suprapapillary portion of the 
stratum Malpighii, increased cells and mitotic figures in the basal and suprabasal cell-
layers, elongation of the rete ridges and long oedematous and often club-shaped papillae. 
In the papillary dermis there is tortuosity and dilatation of the capillaries and a mild 
mononuclear inflammatory infiltrate. Besides accumulation of polymorphonuclear 
leucocytes in the epidermis (micropustules and microabscesses) is a characteristic feature. 
Figure 3 shows the histology of the psoriatic lesion. 
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Fig.3 D= dermis, E= epidermis, SB= str.basale, SC= str. comeum 
At a biochemical level, lesionai skin also shows many differences compared to the 
distant, clinically uninvolved skin. In general, changes seen in the lesion are 
indistinguishable from the normal response of healthy skin to any form of injury. For 
example, epidermal growth factor binding,4 phospholipase С activity,5 protein kinase С 
activity,6 arachidonic acid metabolites7 and ornithine decarboxylase activity8 are all 
increased in the psoriatic plaque. Some differences may exist between clinically 
uninvolved skin and the skin of healthy persons, without a family-history or signs of 
psoriasis. For example, increased activity of phospholipase A2
9
 and ornithine 
decarboxylase10 has been claimed in psoriatics. 
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From a clinical and pharmacological point of view, every patient has his own psoriasis. A 
permanent cure for psoriasis is not yet possible. Therefore, a broad range of symptomatic 
'classical' therapies is being used. Each one has its own specific limitations. 
Corticosteroids induce short remission periods and long-term treatment causes atrophy of 
the skin or even Cushing syndrome. Dithranol (anthralin) immobilizes the patient, since 
treatment necessitates several hours a day. Phototherapy with ultraviolet В radiation or 
photochemotherapy with ultraviolet A combined with psoralen-capsules (PUVA) both have 
cumulative carcinogenic potential. Finally, methotrexate and aromatic retinoids require a 
frequent and sustained supervision of the patient. Therefore, resolution of the pathogenesis 
will provide a more rational, effective therapy; a general statement in medicine. 
1.1.4 The black-box-model 
The biochemical analysis and identification of the enzymes, hormones, cytokines and 
structural proteins that are involved in epidermal inflammation, proliferation and 
differentiation, have provided the basis for our explanation of the normal physiology of 
the skin. But an understanding of how epidermal cells respond to their (pathologic) 
internal and external environments will depend on elucidating their interactions, i.e. the 
behavior of these biochemical agents in time. This will enable us to unravel the etiologic 
factors of the many still unsolved skin disorders; the fascinating challenge of 
dermatological research. 
One possible way to investigate those variables is the use of the so called black-
box model. Give a defined pulse to the epidermis, measure an output system (in time) and 
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argue what might have happened This model can be easily put into practice in animals in 
vivo, especially rodents. This approach allows evaluation of the effects of substances such 
as new drugs and toxic or carcinogenic chemicals. The results of this approach have 
provided many beneficial new insights and therapies, but unfortunately it is not possible to 
extrapolate all these data to the human situation. Both biochemically and histologically 
human skin is not equivalent to rodent skin and many dermatológica! diseases that affect 
mankind are not represented in the animal world. Therefore, in this thesis we worked with 
a black-box model applicable to the human situation in vivo. 
As defined tape stripping of the stratum corneum or irradiation with a single dose 
of ultraviolet В was used to cause a standardized, hyperproliferative response. Tape 
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stripping comprises successive applications of Sellotape to a sharply defined area until the 
surface becomes glistening; removal of the stratum comeum is then considered to be 
complete. This painless procedure causes micro-traumata in membranes, resulting, amongst 
other consequences, in the release of plasma and arachidonic acid metabolites. This finally 
leads to accumulation of polymorphonuclear leukocytes in the skin, an increased number 
of mitoses, hyperplasia and parakeratosis.11,12 There is a close histological similarity 
between the minute papules that develop 6-96 hours after tape stripping and the 
spontaneous pre-pinpoint papules that can be found in the initial stage of the psoriatic 
lesion. 
Irradiation with ultraviolet В is preceded by individual measurements of the minimal 
erythema dose (MED), to correct for skin type and epidermal thickness. During 
experiments 3x the MED is given, causing diffuse damage of epidermal structures,13 
14 
resulting, for example in the release of interleukin-1,14 arachidonic acid metabolites and 
lysosomal hydrolases. Finally this also leads to die hyperproliferative response mentioned 
above, although - probably due to the delaying repair of DNA - in a later stage.13 
As output system we used measurements of the activity of ornithine decarboxylase, an 
enzyme thought to be involved in proliferation and differentiation. Figure 4 shows a 
schematic overview of this black-box-model. 
DRUGS 
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Fig.4 
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1.2 Ornithine decarboxylase (ODC) 
1.2.1 Biochemistry and physiology of ODC 
The first account indicating that putrescine is formed by the decarboxylation of ornithine 
in microorganisms dates back to 1940" and it took until 1968 before mammalian ODC 
was discovered17. Soon afterwards it became clear that its activity is always enhanced in 
response to anabolic stimuli18, it possesses an extremely short molecular half-life of only 
10-20 min19, and pyridoxal phosphate is used as a cofactor20. 
In fact, the only important biochemical function of ODC is to catalyze the 
conversion of L-omithine into putrescine and C02. A variety of mammalian ODC's is 
specific for the L-isomer of ornithine and does have KM values of about 0.1 mM21. In 
vitro, mammalian ODC's are strongly dependent on the presence of reducing agents for 
maximal activity22, but except for pyridoxal phosphate no other activators of the enzyme in 
normal tissues are known. Many extrahepatic cells (including keratinocytes), which lack 
the other enzymes of the urea cycle, contain arginase and are able to generate ornithine 
from arginine and use ornithine as a substrate for ODC22,23. In animals and humans, 
ornithine is also available from the plasma. 
Providing putrescine for polyamine synthesis is the physiologic function of ODC. 
Putrescine in turn is indirectly converted into spermidine and spermine (the "genuine" 
poly-amines) by S-adenosyl-methionine-decarboxylase (SAM-DC). Cells cannot grow at 
their normal rate if either function is prevented, unless alternative pathways for polyamine 
synthesis are present (i.e. in mutant E. coli24 or mammalian cells25) or exogeneous 
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polyamines are provided (i.e. by diet26 or gut-flora27). Many negative and positive feed-
back mechanisms do exist in these pathways28 (see Fig. 5). Putrescine directly inhibits 
ODC and stimulates S-adenosyl-methionine decarboxylase (SAM-DC); at the ribosomal 
level spermidine blocks the translation of ODC mRNA and spermine blocks the translation 
of SAM-DCmRNA. Spermine and spermidine can be reconverted into putrescine by their 
respective N-acetyltransferase, however, putrescine cannot be reconverted into ornithine. 
Therefore, at least in cell types containing very low basal ODC activity (epidermis!), ODC 
can be considered as the rate-limiting step in polyamine biosynthesis. 
•xtncmllular 
ornithine 
arginili· 
Fig.5 
Under physiological conditions polyamines behave as organic cations and therefore are 
presumed to associate with anionic binding sites in e.g. nucleic acids and proteins through 
electrostatic interactions29. There are indications for specific binding of spermine with 
tRNA and DNA, which probably stabilizes the confirmation of the anticodon loop of 
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tRNA and induces bending and aggregation of DNA. Evidence also exists that the 
chromatin structure is stabilized by polyamines30. They are involved in the synthesis of 
macromolecules as well. Protein synthesis is clearly blocked by inhibition of polyamine 
synthesis, as shown by a decrease in the incorporation of radioactive amino acids both in 
vitro31 and in vivo52. The mechanism by which polyamines are involved in DNA 
replication are as yet unclear. Perhaps replicón initiation rather than chain elongation is 
affected by polyamine deficiency33. During inhibition of ODC, the level of decarboxylated 
SAM becomes highly increased, which results in inhibition of SAM mediated DNA 
methylation34. This process may contribute to the antiproliferative effects of cellular 
polyamine depletion by inhibition of ODC. 
Finally, of the many functions polyamines have on various processes in living 
cells, another important, although rather poorly documented one has to be mentioned. 
They can be covalently linked with glutamate residues of proteins by the enzyme 
transglutaminase35'36. This results in crosslinking of proteins, a specific differentiation 
process in the formation of the stratum comeum37. However, confusion remains in the 
early literature especially regarding the differences between intracellular / soluble and 
membrane-bound / "epidermal" transglutaminases. Besides, polyamine synthesis inhibitors 
induce terminal differentiation of certain tumors.38 
In summary, from a biochemical point of view, we may conclude that ODC seems 
to be a valuable tool in studying the regulation processes that are involved in at least 
proliferation and maybe also differentiation. In the next paragraph its applications and 
present status in dermatological research are discussed. 
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tl1 Epidermal ODC39·4041 
ODC activity is normally very low or not measureable in undamaged, healthy skin of both 
rodents and humans. In rodents, ODC induction follows the application of certain tumor 
promoting phorbol esters (peak after 6-8 h) or irradiation with ultraviolet-B (peak after 24 
h). In addition, hair plucking and tape stripping have been shown to induce ODC; the 
latter with a similar induction curve following application of tumor promoting agents 
(TPA). Increasing age has been reported to decrease the ability of inducing epidermal 
ODC, at least in rats. Except for the application of TPA, the same modes of induction 
have been studied in humans. However, in the case of UV-B irradiation only, a complete 
induction curve is available, comparable with rodents. No data are known regarding the 
effects of increasing age. 
Several drugs that block ODC induction have been mentioned in the literature, 
revealing some insight into the biochemical pathways of ODC induction and hence 
epidermal (hyper)proliferation. In rodents corticosteroids, both cyclo-oxygenase- and (or) 
lipoxygenase-inhibitors, retinoic acid, vitamin D3 and inhibitors of protein kinase С (PKC) 
have been shown to reduce ODC induction. In humans (at least in vivo) neither ligands of 
the steroid hormone receptor superfamily, eicosanoids nor PKC-inhibitors have been 
investigated regarding their influence on epidermal ODC induction. 
In psoriatic patients, ODC activity is clearly elevated in the lesionai plaque 
compared to the clinically uninvolved skin. This increased ODC activity proved to be 
reduced in vivo by corticosteroids and retinoic acid. A few reports only described slightly 
increased ODC activity in the uninvolved skin compared to the epidermis of healthy 
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controls and in a single report this difference became even larger following an induction 
stimulus. 
The data mentioned in this chapter lead to an hypothetical explanation regarding 
the pathways of ODC induction in rodent epidermis. In an oversimplified way, this has 
been scheduled in Fig. 6. 
Fig. 6 
Legend to Fig. 6 AA= arachidonic acid, CS= corticosteroid, COG= cyclooxygenase, 
D3= vitamin D3, DAG= diacylglycerol, EGF-R= epidermal growth factor receptor, LC= 
lipocortin, LG= lipoxygenase, LT= leucotrienes, PG= prostaglandins, PKC= protein kinase 
C, PLA2= phospholipase A2, PLC= phospholipase C, RA= retinoic acid, TGFa= 
transforming growth factor a, TPA= tetradecanoylphorbol-acetate, UVB= ultraviolet B, X= 
transcription factoids) 
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IJ Aim of the thesis 
In paragraph 1.1 and 1.2 it has become clear that the investigation of induction pathways 
of ODC may lead to a better understanding of the (patho)physiology of proliferation and 
may give insight into therapeutic mechanisms of antipsoriatics. And especially in 
paragraph 1.2.2 it is obvious that many questions regarding epidermal ODC induction still 
have to be answered in humans, because data that are well established in rodent epidermis 
have never been checked in humans and also since some data are conflicting even for 
rodent epidermis. Concerning the latter, for example, inhibition of arachidonic acid release 
by corticosteroids surely blocks ODC induction, but whether its biochemical "end-
products", prostaglandins and/or leucotrienes are responsable for this action, remained 
uncertain. 
Therefore we started first investigating induction curves following tape stripping of 
both the epidermis of healthy controls and the uninvolved skin of psoriatic patients, in 
order to establish: a) are basal ODC activity levels measurable?, b) what is the time and 
level of the peak of maximal ODC activity following this induction technique? and c) do 
both basal and peak ODC activities differ between healthy subjects and psoriatic patients 
(indicating a key in the pathogenesis)? This will be described in chapter П; in addition a 
first attempt was made to investigate the influence of the arachidonic acid cascade on 
epidermal ODC induction by the use of a topical corticosteroid and a systemical 
cyclooxygenase inhibitor. In chapter Ш the effects of a topical cyclooxygenase- and 
lipoxygenase- inhibitor regarding epidermal ODC induction are reported. 
21 
Vitamin Dj has been shown to block ODC induction in rodent epidermis only. 
Therefore it became interesting to find out whether this was also true in human epidermis 
and moreover if this would explain a / the mode of action of calcipotriol, the new anti-
psoriatic vitamin D3 analogue. Besides, since so many ligands of the so-called steroid 
hormone receptor superfamily (corticosteroids, retinoic acid, vitamin Dj) proved to be both 
inhibitors of ODC induction and potent antipsoriatic drugs, it seemed of interest to study 
the effects of another member, estriol. These questions are addressed in chapter Г . 
Combining the data of chapter ΙΠ and Г , raised the possibility that ODC could be 
used as a marker-enzyme to test (new) antipsoriatic therapies. In chapter V, therefore, the 
concept that inhibitors of epidermal ODC induction would be antiproliferative drugs was 
tested for a) sphingosine, a potent PKC-inhibitor, b) isoquinoline, possibly a PKC inhibitor 
or otherwise an active compound of antipsoriatic coal-tar, c) tannic acid, a substance that 
had proven empirically to inhibit ODC induction in rodent skin and d) cyclosporin A, a 
recently registered antipsoriatic drug with conflicting data regarding its influence on 
epidermal proliferation. 
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Chapter Π 
THE INDUCTION OF ODC FOLLOWING 
SELLOTAPE STRIPPING 

2.0 INDUCTION OF ODC FOLLOWING SELLOTAPE STRIPPING IN 
NORMAL AND PSORIATIC SKIN 
W.P. Arnold, C.A.E.M. van Hooijdonk, P.D. Mier, P.C.M. van de Kerkhof 
This work was presented at the ΣΟ* annual meeting of the E.S.D.R., Turin, June 9th - 12* 
1990 
Ornithine decarboxylase (ODC) was measured in the epidermis of healthy volunteers and 
the uninvolved skin of psoriatic patients at various times after sellotape stripping. Basal 
levels were less than 1 pmol/min/mg protein. Activity peaked to a maximum of 86 
pmoVmin/mg protein after 8 h; this was followed by an abrupt decline to a lower level 
which remained relatively constant for at least 36 h. No difference was seen between the 
response of controls and psoriatic patients. Pretreatment with topical corticosteroids 
reduced peak ODC levels to about one-half, but oral indomethacin had no effect 
INTRODUCTION 
ODC is the rate-limiting enzyme for polyamine biosynthesis. Cellular ODC levels are 
linked to the phase of the cell cycle. Quiescent or early G, cells show low activity, but 
there is an abrupt increase in late G, which provides the polyamines that are required for 
DNA synthesis. Thus, ODC is a valuable 'marker enzyme' for cellular proliferation.1,2 
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Most of the published investigations regarding epidermis have used rodents, 
where ODC induction has been demonstrated following injury (e.g. tape stripping1 or 
ultraviolet radiation4"9) or the application of tumour-promoting agents such as 
tetradecanoylphorbol acetate (TPA).10*12 Several groups have reported increased ODC 
levels in the lesions of psoriasis, and shown that these normalize following therapy.2 More 
recently it has been claimed that ODC is 'hyper-inducible' in the psoriatic patient13 
However, to our knowledge the time-course of ODC induction following injury has never 
been investigated in human skin. Here we report ODC levels following tape stripping in 
healthy controls and psoriatic patients, and describe the effects of pretreatment with topical 
corticosteroids or oral indomethacin. 
METHODS 
Subjects 
The control group consisted of 19 volunteers (10 male, nine female; age range 21-57 
years), none of whom had a personal or family history of psoriasis. The psoriatic group 
comprised eight patients (five male.three female; age range 17-55 years) with chronic 
plaque psoriasis, who had received no therapy for at least 4 weeks prior to investigation. 
The use of aspirin or other NSAIDs was specifically excluded in all subjects during or 
immediately prior to experiments. Informed consent was obtained from all the subjects and 
the study had the approval of the Medical Ethics Committee. 
SellotapeR stripping was carried out as described previously14, using a plastic 
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template to restrict the damage to sharply defined areas of 2 χ 3 cm, and the stripped sites 
covered with a non-occlusive dressing. At appropriate times, epidermal slices of 
approximately 1 cm2 were cut from the centre of each site using a Castroviejo keratotome 
(Storz Instr. Co.) set for a depth of 0.3 mm after cooling the skin with an ethylchloride 
spray. Biopsies were snap frozen in liquid nitrogen and kept at this temperature prior to 
analysis. 
Six volunteers were pretreated with oral indomethacin, taking 75 mg 14 h and 2 h 
prior to tape stripping. A second group, consisting of five volunteers were pretreated with 
either topical betamethasone dipropionate or a base cream under occlusion for 14 h prior 
to stripping. The sites were thoroughly cleaned with 70 % alcohol immediately prior to 
stripping, and biopsies taken for ODC measurement after a further 8 h. 
ODC measurement 
This was a modification of a previously described methodls.Biopsies were homogenized in 
0.5 ml of a freshly prepared buffer (50 mM Tris, 50 pM pyridoxal phosphate and 2 mM 
dithiothreitol at pH 7.3) using an ice-cooled Potter-type grinder. The reaction was initiated 
by adding 80 μΐ of homogenate to 20 ul of a solution containing 2 mM L-omithine and 
0.1 pCi L-[l-14C]omithine (New England Nuclear, Boston, MA, U.S.A.) in plastic tubes. 
After fitting each tube with a plastic cap carrying 5 cm2 filter paper moistened with 20 μΐ 
10 % КОН, the mixture was incubated at 37 °C for 45 min. The reaction was stopped by 
adding 100 μΐ IM HCl, and incubated at 37°C for a further 30 min to ensure complete 
absorption of M C0 2 on to the paper. Radioactivity was measured by scintillation counting 
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using an Isocap-300 (Searle Instruments B.V.); the paper was placed directly into the 
scintillation vial containing 4.5 ml scintillation fluid (Aqua Luma Plus) without prior 
dissolution. All samples were assayed in duplicate, and a complete reagent blank was 
included with each batch. 
Preliminary experiments were carried out as described above to verify the 
linearity of the reaction with respect to time for incubation periods up to 60 min. 
Protein measurement 
An aliquot of the homogenate was diluted 1 : 5 with homogenizing buffer and centrifuged 
(10 min, 15,000 g). Protein was determined in the clear supernatant by direct fluorescence 
(^EX= 278 nm, λΕΜ= 340 nm) using bovine serum albumin as standard. Linearity was 
confirmed in the range of 1-200 pg/ml protein. 
Statistical methods 
Analysis of variance was carried out for time and diagnosis using the SAS package and a 
VAX computer system. 
RESULTS 
The total reagent blank (including instrument background) averaged about 20 c.p.m. If an 
increment of 5 c.p.m. above this level is regarded as the minimum required to detect ODC 
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activity, and assuming a typical value of around 250 pg/ml for the concentration of soluble 
protein in the original homogenate, the absolute sensitivity of the method may be 
calculated to be about 1 pmol C02 released per min per mg protein. The assay was linear 
with respect to time for about 45 min, but showed a clear decline at 1 h. An incubation 
period of 45 min was therefore used for routine measurements. The reproducibility was 
good and duplicate assays averaged within ± 4.3 % of the mean. 
No ODC activity could be detected in biopsies taken immediately after stripping 
(i.e. less than 1 pmol/min/mg protein). The time curve during the following 36 h is shown 
in Figure 1. An abrupt increase at 4 h reached a peak of 86 pmol/min/mg protein at 8 h. 
This was followed by an equally rapid diminution, reaching a level which remained 
relatively constant until at least 36 h post-stripping. The 24-h specimens, although 
averaging rather higher than the 16 h and 36 h values, did not differ significantly from the 
latter groups. No significant difference in ODC activity was observed between healthy 
volunteers and the clinically uninvolved skin of psoriatic patients at any of the times 
studied (4, 8 and 16 h). 
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ODC levels in healthy and psoriatic uninvolved epidermis at various times after tape stripping. All values are 
expressed as pmol/min/mg protein (mean ± SEM). Numbers of specimens are shown at the top of the bars. 
The peak ODC levels in sites pretreated with betamethasone dipropionate averaged 45 
pmol/min/mg protein, around one-half the value of either the untreated controls or the sites 
which had been occluded with base only (Table 1). By contrast, subjects receiving oral 
indomethacin prior to biopsy did not show any significant difference from the control 
group. 
Table 1 Effects of pretreatment with indomethacin or betamethasone dipropionate on epidermal ODC measured 
8 h after tape stripping. Values are expressed as pmol/min/mg protein (mean ± SEM). The control values for the 
indomethacin experiment are from Figure 1; for the betamethasone dipropionate experiment the control sites were 
pretreated with base cream (betametasone dipropionate vs. control, Ρ < 0.05) 
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Treatment Experimental group Control group 
Indometacin 82 ± 8 (η = 6) 86 ± 8 (η = 12) 
Betamethasone 45 ± 7 (n = 5) 87 ± 5 (n = 5) 
dipropionate 
Table 1 
DISCUSSION 
The time-course of ODC induction in human subjects following stripping was similar to 
that following the application of tumor-promoting agents to mice, where enzyme activities 
peak around 6-10 h.10"12 A similar value of 6 h has been reported following stripping the 
skin of the hairless rat,3 but peak ODC levels were seen 14 - 28 h following treatment of 
mice with UVB.0,8·9 Absolute values in rodent epidermis show wide variation, probably 
due to differences in methodology but most groups report basal ODC activity as being too 
low to measure. 
Only one previous report has appeared regarding the effect of injury on ODC 
levels in human subjects.13 These workers used an arbitrary induction period of 6 h, and 
compared the response of psoriatic patients to Sellotape" stripping with that of healthy 
controls. Their findings differ in several respects both from previous work and to our 
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present observations. All specimens showed remarkably high basal levels, no significant 
difference being reported between psoriatic lesion and normal skin. At 6 h, ODC activity 
had doubled in healthy subjects, but in psoriatic patients had risen by a factor five- to ten 
fold. By contrast, our data (Fig.I) indicate at least an 80-fold stimulation which is identical 
in normal and psoriatic uninvolved skin. The reasons for these discrepancies are not clear. 
The only significant methodological difference is that the previous workers do not mention 
correcting their data for a reagent blank; this could account for the higher basal activity 
and hence the lower induction ratios. 
There is considerable evidence that an arachidonic acid metabolite (presumably a 
cyclooxygenase product) is required for ODC induction. Thus the response to stimuli such 
as TPA applied to the skin of rodents is blocked by corticosteroids or cyclooxygenase 
inhibitors.16"19 However, this data is difficult to extrapolate to human skin, especially using 
appropriate routes of administration and dosage schedules. We have shown in this study 
that betamethasone dipropionate results in a clear reduction of ODC levels following 
injury (Table Γ). Thus, in addition to their anti-inflammatory and other effects, 
corticosteroids may diminish proliferation via a reduction in polyamine availability. 
The induction time following stripping was similar to that reported for TPA. 
Since the induction of ODC is mediated via activation of protein kinase C,11 either directly 
(by TPA) or indirectly following injury, we conclude that the sequence of events between 
injury and protein kinase С activation is fairly rapid. Thus, the long delay between 
stripping and G„ recruitment20 occurs 'distal' to protein kinase activation, and cannot be 
explained by the slow release or diffusion of cytokines resulting from stripping. Also, 
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because the first wave of DNA synthesis begins around 32 h after stripping,10 what is the 
function of polyamines peaking virtually a full cell cycle before this time? The reasons for 
this await further research. 
REFERENCES 
1 Lowe NJ. Epidermal ornithine decarboxylase, polyamines, cell proliferation and tumor promotion. Arch 
Deimatol 116: 822-825, 1980 
2 Lowe NJ. Cutaneous polyamines and their biosynthetic enzymes. In: Psoriasis (HH Roenigk, Ш 
Maibach, eds). New York: Dekker, 1985; 249-254 
3 Bouclier M, Shroot В, Dionisius V et al. A rapid and simple test system for the evaluation of the 
inhibitory activity of topical retinoids on Sellotape stripping induced ODC activity. Dermatologica 169: 
242, 1984 
4 Lowe NT, Verma AK, Boutwell RK. Ultraviolet light induces epidermal ornithine decarboxylase 
activity. J Invest Dermatol 71: 417-418, 1978 
5 Veima AK, Lowe NJ, Boutwell RK. Induction of mouse epidermal ornithine decarboxylase activity 
and DNA synthesis by ultraviolet light Cancer Res 39: 1035-1040, 1979 
6 Lichti U, Patterson E, Yuspa SM. Retinoic acid differentially inhibits the induction of ODC by TPA 
and by germicidal ultraviolet light free Am Assoc Cancer Res 20: 105, 1979 
7 Lowe NJ, Breeding J. Antiinflammatory drug effects on ultraviolet light induced epidermal ornithine 
decarboxylase and DNA synthesis. J Invest Dermatol 74: 418-І20, 1980 
8 Lowe NJ, Breeding J. Retinoic acid modulation of ultraviolet induced epidermal ornithine 
decarboxylase activity. J Invest Dermatol 78: 121-124, 1982 
9 Nemoto O, Koizumi H, Aoyagi T. A novel synthetic vitamin Α-like compound (E-5166) inhibits UVB-
stimulated epidermal ODC activity. Arch Dermatol Res 278: 407-409, 1986 
37 
10 Nakadate Τ, Yamamoto S, Aizu E, Kalo R. Inhibition of TPA-induced tumor promotion and epidermal 
ODC activity in mouse skin by palmitoylcarnilhine. Cancer Res 46: 1589-1593, 1986 
11 Gupta AK, Fisher GJ, Elder JT et al. Sphingosine inhibits TPA-induced inflammation, ODC activity 
and activation of protein kinase С in mouse skin. J Invest Dermatol 91: 486-491,1988 
12 Yamamoto S, Kiyoto I, Aizu E et al. Differential inhibition by staurosporine, a potent protein kinase С 
inhibitor, of TP A caused skin tumor promotion, epidermal ODC induction, hyperplasia and 
inflammation. Carcinogenesis 10: 1315-1322, 1989 
13 Bouclier M, Elbaze Ρ, Milano G et al. Hyper-induction of skin ornithine decarboxylase activity in 
psoriatic patients. Br J Dermatol 115: 193-198,1986 
14 Van de Kerkhof PCM, van Rennes H, de Grood RM et al. Response of the clinically uninvolved skin 
of psoriatic patients to standardized injury. Br J Dermatol 109: 287-294, 1983 
15 Hayashi SI, Kameji T. Ornithine decarboxylase (rat liver). Method Enzymol 94: 154-158, 1983 
16 Verma AK, Ashendel CI, Boutwell RK. Inhibition by prostaglandin synthesis inhibitors of the 
induction of epidermal ODC activity, the accumulation of prostaglandins and tumor promotion caused 
by TPA. Cancer Res 40: 308-315,1980 
17 Nakadate T, Yamamoto S, Ishii M, Kato R. Inhibition of TPA-induced ep[idermal ODC activity by 
phospholipase A2 inhibitors and lipoxygenase inhibitor. Cancer Res 42: 2841-2845,1982 
18 Nakadate T, Aizu E, Yamamoto S et al. Inhibition of teleocidin-caused epidermal ODC induction by 
phospholipase A2-, cyclooxygenase- and lipoxygenase-inhibitors. Japan J Pharmacol 37: 253-258,1985 
19 Uzumakl H, Yamamoto S, Kato R. Effects of lipoxygenase- and cyclooxygenase inhibitors on the 
induction of ODC by TPA and isoprotenerol in mouse tissues in vivo. Carcinogenesis 7: 289-294,1986 
20 Bauer FW, Boezeman JBM. Flow cytometric methods in human skin with respect to cell cycle 
kinetics. In: Psoriasis: Cell Proliferation (NA Wright, RS Complejohn, eds). Edinburgh: Churchill 
Livingstone 1983; 104-105 
38 
Chapter Ш 
INFLUENCE OF EICOSANOIDS ON 
EPIDERMAL ODC INDUCTION 

3.1 CYCLOOXYGENASE PRODUCTS DO NOT PARTICIPATE IN THE 
INDUCTION OF ODC IN HUMAN EPIDERMIS 
W.P. Arnold, A.M.E. Lintsen, P.C.M. van de Kerkhof, P.D. Mier 
This work was presented at the 21st annual meeting of the E.S.D.R., Copenhagen, June 
1" - 4*. 1991 
Extensive animal data have suggested that prostaglandins are involved in the epidermal 
induction of ornithine decarboxylase (ODC). The aim of the present study was to 
investigate their role during the induction of hyperproliferation in human skin. 
Two groups of experiments were carried out. In the first topical indomethacin 
(Elmetacin11) or vehicle only were applied under occlusion on the backs of healthy 
volunteers, followed by sellotape stripping after 1 h; biopsies for ODC measurement were 
taken after a following 8 h. No difference was found between indomethacin versus control. 
In the second experiment test sites were irradiated with 3x the Minimal Erythema Dose of 
UV-B, immediately followed by application of indomethacin or vehicle only on the UV-
irradiated sites. After 8 h biopsies were taken. The degree of erythema was markedly 
reduced in all the indomethacin treated sites, compared to the control, confirming that 
dosage and penetration were adequate. Nevertheless, ODC levels were again similar on 
both sites. These data indicate that cyclooxygenase products in human epidermis do not 
contribute to the induction of ODC. 
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INTRODUCTION 
Ornithine decarboxylase (ODQ is the rate-limiting enzyme in the biosynthesis of 
polyamines, that are required for DNA synthesis. Therefore elevation of ODC activity is 
seen in various hyperproliferative situations. Basal ODC-levels are not detectable in 
normal epidermis, but induction of this enzyme has been demonstrated following injury 
(e.g. sellotape stripping, UV-irradiation ' ) or application of tumour promoting 
. [5,6] 
agents. 
Extensive animal data have suggested that eicosanoids are essential for the 
epidermal induction of ODC. In vivo studies in rodents report that the ODC induction 
[5-9] is markedly suppressed by cyclooxygenase inhibitors, by lipoxygenase inhibitors! 10-
12] or both. ' Thus it remains uncertain whether prostaglandins, leukotrienes or both 
contribute to the epidermal ODC induction. These contradictory facts raise the question of 
what pathway is responsible in human skin. 
The purpose of this study was to clarify whether prostaglandins are involved in the 
epidermal induction of ODC. We describe the effects of the topical cyclooxygenase 
inhibitor Elmetacin11 (indomethacin 1%) on trauma- and UV-B induced ODC in human 
epidermis. 
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METHODS 
Sellotape stripping was used as an inflammatory insult because data regarding the time· 
[2] 
course and enzyme peak activities are well documented. To ensure that the 
indomethacin reservoir in the stratum comeum remained available during the induction 
period we designed an additional experiment using UV-B. Epidermal ODC-activity was 
[2] 
determined at its maximal level, 8 h after stripping. By contrast maximum ODC-levels 
following UV-B irradiation are not achieved until 24 h, which we confirmed in 
preliminary investigations (data not shown). Restricted by the pharmacokinetics of 
indomethacin and for practical reasons, we nevertheless took skin samples 8 h after 
irradiation, when the ODC-activity was sufficient to permit accurate quantification. 
Stripping experiment 
This consisted of 9 healthy volunteers (4 male, S female, age range 18-58 years), without 
known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The use of 
aspirin or other NSAIDs was not allowed during or immediately prior to the experiment 
Indomethacin 1% (40 μΐ/cm2) in an isopropanol solution, (Elmetacin11, Luitpold Werk, 
München, BRD) or vehicle only, were applied within a plastic cylinder (1.75 cm2) on two 
sites of the backs, evaporated with air under pressure and occluded with a non-toxic 
plastic foil. After 1 h sellotape stripping was carried out on both sites as described 
[2] 
previously, using a plastic template to restrict the damage to the pretreated areas. These 
were covered with a non-occlusive dressing. After a further 8 h biopsies (0.5 cm2, 0.3 
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mm) were taken from the centre of each site using a Castroviejo Keratotome (Storz 
Instrument Co.) after cooling the skin with an ethylchloride spray. Biopsies were washed 
in cold phosphate buffered saline. After drying between filterpaper and weighing, they 
were snapfrozen in liquid nitrogen and kept at -20°C prior to analysis. 
UV-B experiment 
This again consisted of 9 healthy volunteers (4 male, 5 female age range 18-28 year), 
subject to the previous restrictions. The minimal erythema dose (MED) of every individual 
was measured, using a high-pressure Hg source (SolamedR) at a distance of 20 cm. Three 
sites of their backs (2 cm2) were irradiated with a dose of 3x the MED. Immediately after 
irradiation, application of indomethacin or vehicle only was carried out In order to 
exclude any effect of the vehiculum in itself, biopsies were also taken of irradiated sites 
without treatment The test-sites were left under occlusion for 8 h and biopsies were taken 
for ODC measurement as before. 
ODC-measurement 
This was a modification of a previously described method. Biopsies were homogenized 
in 0.5 ml of a freshly prepared buffer (50 mM Tris, 50 μΜ pyridoxal phosphate and 2 mM 
dithiothreitol at pH 7.3) using an ice-cooled Potter-type grinder. The reaction was initiated 
by adding 80 μΐ of homogenate to 20 μΐ of a solution containing 2 mM L-ornithine and 
14 0.1 μΐ L-[l- C] ornithine (0.1 mCi/ml, specific activity 52.3 mCi/mmol; New England 
Nuclear, Boston, MA, USA) in plastic tubes. After fitting each tube with a plastic cap 
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carrying S cm2 filter paper moistened with 20 pi 10% KOH, the mixture was incubated at 
37°C for 43 min. The reaction was stopped by adding 100 ul 1 M HCl, and incubated at 
37°C for a further 30 min to ensure complete absorption of 14C02 onto the paper. The 
paper was placed directly into a scintillation vial containing 4.0 ml scintillation fluid 
(Aqua-luma Plus) without prior dissolution and radioactivity was measured by scintillation 
counting using a Pharmacia Wallac 1410. All samples were assayed in duplicate, and a 
complete reagent blank was included with each batch. 
Protein-measurements 
An aliquot of the homogenate was diluted 1:5.5 with homogenizing buffer and centrifugea 
(10 min, 12.000 rpm). Protein was determined in the clear supernatant by direct 
fluorescence (λρ =278 nm, λ., =340 nm) using bovine serum albumin as standard. 
RESULTS 
The total reagent blank (including instrument background) averaged about 22 dpm. 
Duplicate assays averaged within + 2.4% of the mean. In preliminary experiments dosage 
and duration of indomethacin application were investigated; doubling of both variables did 
not alter the ODC-levels. 
In the first experiment, ODC activity was measured following sellotape stripping. 
Pre-treatment of the sites with indomethacin resulted in ODC levels averaging 160 + S.E. 
30 pmol/min/mg protein; this was not significant different from those pre-treated with 
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vehicle only (129 + 30 pmol/min/mg protein; Ρ > 0.0S). Expressed on a weight basis 
activities were 2.9 + S.E. 0.6 and 2.6 + 0.6 pmol/min/mg respectively, again similar (P > 
0.05). 
The second experiments, using UV-B irradiation to stimulate ODC induction, were 
done to rule out the possibility that an intact stratum comeum might be required to 
provide a "reservoir" of indomethacin during the induction period. On a protein basis, 
ODC levels for UV + indomethacin, UV + vehicle and UV only were 13 + S.E. 2.2, 14 + 
l.S and 16 + 2.3 pmol/min/mg protein respectively; on a weight basis the values were 
0.21 + S.E. 0.05, 0.24 + 0.05 and 0.26 + 0.06 respectively. The effects of indomethacin 
were not statistically significant using either reference variable (P > 0.05) in both cases). 
Remarkably, however, indomethacin application resulted in a clear reduction of erythema 
in all 9 subjects compared with UV + vehicle or UV only. 
DISCUSSION 
[181 The capacity of indomethacin to block prostaglandin biosynthesis is well documented. 
It has become clear from our results that prostaglandins do not contribute to the in vivo 
induction of ODC in human skin. This is especially clear after UV-B irradiation, where 
the test-sites treated with indomethacin showed a marked reduction of erythema, which 
established beyond doubt that dosage and penetration of the cyclooxygenase inhibitor were 
adequate. 
Investigations in animals using UV irradiation showed that the release of 
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cyclooxygenase products was dependent upon both dose and wavelength,11 ' observed 
prostaglandin concentration paralleled the intensity of erythema. Reduction of erythema 
and oedema after topical application of indomethacin was also reported. It has been 
suggested that leukotrienes, act initially direct on epidermal cells, for example by 
[22] 
stimulating the transcription of interleukin-1 within 15 min of cell activation. On the 
other hand cyclooxygenase metabolites act mainly indirectly via other cell types, such as 
[18] 
capillary endothelial cells. The epidermal injury-induced prostaglandins cause 
vasodilatation, followed by infiltration of inflammatory cells, such as polymorphonuclear 
leucocytes, in a later stage. The release of their "aggressive" mediators would then 
continue the inflammatory, hyperproliferative response, including induction of ODC. Thus 
the indirect inhibition of ODC would only become measurable after at least 24 h of 
continued prostaglandin inhibition by indomethacin. 
Further investigation are in progress to test the validity of this concept 
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3.2 THE INDUCTION OF ODC IN HUMAN EPIDERMIS IS INDEPENDENT 
OF LD70XYGENASE AND CYCLOOXYGENASE PATHWAYS 
W.P. Arnold, B.J.H. Pennings, P.C.M. van de Kerkhof 
In vivo studies in rodents suggest that prostaglandins and/or leukotrienes are involved in 
the epidermal induction of ornithine decarboxylase (ODC). Recently, we have shown that, 
in human epidermis, prostaglandins are not involved in this process. Here we report the 
role of leukotrienes in epidermal ODC induction in human skin. Topical flufenamic acid 
(Dignodolin11), vehicle, or nothing was applied under plastic occlusion to three sites on the 
backs of healthy volunteers. This was followed 1 h later by SellotapeR stripping. After 
renewed application and occlusion for 8 h, biopsies were carried out for the estimation of 
ODC levels. There were no significant differences in the levels of ODC between the 
flufenamic acid treated and control sites. To confirm this finding, test sites were irradiated 
with 3 MED of UVB. This was immediately followed by the application of flufenamic 
acid, vehicle, or nothing to the three irradiated sites. After 8 h, biopsies were taken, and 
the levels of ODC were again similar in the flufenamic acid- and the vehicle-tested sites. 
The data indicate that, following SellotapeR stripping or UVB irradiation, neither 
lipoxygenase nor cyclooxygenase products contribute to the in vivo induction of ODC in 
human epidermis. 
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INTRODUCTION 
Ornithine decarboxylase (ODC) is the rate-limiting enzyme for the biosynthesis of 
polyamines. Because polyamines are required for the DNA synthesis, ODC is a valuable 
'marker enzyme' for cellular proliferation. In normal epidermis, ODC is not detectable, 
but, in various hyperproliferative situations, an elevation of ODC activity is seen. The 
enzyme can be induced by injuries such as SellotapeR stripping1·2 and UV irradiation,3,4 or 
by application of tumor-promoting agents such as tetradecanoyl-phorbol-acetate СГРА).5,6 
In vivo studies in rodents indicated that ODC induction was suppressed by 
cyclooxygenase inhibitors,*"9 lipoxygenase inhibitors10"12 or both.13,14 Therefore, it has been 
suggested that prostaglandins, leukotrienes, or both are essential for epidermal ODC 
induction.5"14 Recently we have shown that, in human epidermis, prostaglandins do not 
participate in the induction of ODC.15 Here we address the role of leukotrienes in this 
process. 
This study was carried out to determine whether leukotrienes are essential to the 
induction of ODC in human epidermis by examining the effect of the topical 
lipoxygenase- and cyclooxygenase inhibitor flufenamic acid (Dignodolin") on both trauma­
and UVB-induced ODC in human epidermis. Flufenamic acid penetrates the epidermis 
without degradation16 and a 3% concentration is sufficient for suppression of lipoxygenase 
and cyclooxygenase in human skin.17'19 No data are available regarding the effect of the 
agent on protein kinase С 
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METHODS 
SellotapeR stripping was used as an in vivo model for epidermal proliferation, because the 
data concerning the time course and enzyme peak activities are well documented.2 To 
ensure that the flufenamic acid reservoir in the stratum comeum remained available during 
the induction period, an additional experiment was performed using UVB. The maximum 
epidermal ODC activity is measured 8 h after stripping2 and 24 h after UVB irradiation.20 
For practical reasons, including the pharmacokinetics of flufenamic acid, we nevertheless 
took skin samples 8 h after irradiation, as the level of ODC activity was then sufficient for 
accurate quantification. 
Stripping experiment 
This experiment involved 8 healthy volunteers (5 male, 3 female, age range, 20-26 years). 
None were allowed to use none-steroidal anti-inflammatory drugs after, during, or 
immediately prior to the experiment. About 200 mg of Dignodolin* cream containing 3% 
flufenamic acid (Luitpold Werk, München, Germany) and the same amount of vehicle 
were each applied on a 3 cm2 site on the back and then occluded under non-toxic plastic 
sheets. After 1 h, SellotapeR stripping2 was carried out at these two sites and at an 
untreated control site. Again, flufenamic acid or vehicle were each applied on the 
pretreated sites. The three sites were then covered with a non-toxic plastic occlusion. After 
a further 8 h, biopsies (1 cm2 χ 0.2 mm.) were taken from the centre of each site using a 
Castroviejo keratome under local anaesthesia produced by cooling the skin with ethyl 
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chloride. The biopsies were washed briefly in cold phosphate-buffered saline, snap frozen 
in liquid nitrogen, and kept at -20°C prior to analysis. 
UVB experiment 
This experiment also involved 6 healthy volunteers (3 male, 3 female, age range 20-27 
years). The minimal erythema dose (MED) for each individual was determined and three 
sites on their backs (3 cm2) were each irradiated with 3 MED. Within one minute after 
irradiation, flufenamic acid, the vehicle only, or nothing was applied to these sites, which 
were left under plastic occlusion for 8 h. Keratome biopsies (1 cm2 χ 0.2 mm) were taken 
to determine the ODC levels. 
Measurement of ODC 
This was a modification of a previously described method.21 The biopsies were 
homogenized in 0.5 ml Tris buffer at pH 7.3 using an ice-cooled Potter-type grinder. The 
reaction was initiated by adding 80 μΐ of homogenate to 20 pi of a solution containing 
0.5mM L-omithine and 0.1 pCi L-[l-MC]-omithine (specific activity 52.3 mCi/mmol; New 
England Nuclear, Boston, MA, U.S.A.) in plastic tubes. After fitting each tube with a 
plastic cap with 5 cm2 filter paper moistened with 20 pi 10% КОН, the mixture was 
incubated at 37°C for 45 min. The reaction was stopped by adding 100 ul IM HCl, and 
incubated at 37°C for a further 30 min to ensure complete absorption of "COj onto the 
paper. The paper was then placed into a scintillation vial containing 4 ml scintillation fluid 
without prior dissolution, and the radioactivity measured. All samples were assayed in 
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duplicate and a complete reagent blank was also included. 
Protein measurements 
An aliquot of the homogenate was diluted with the buffer and centrifuged. The protein 
content was determined in the clear supernatant by direct fluorescence (λ EX=278 nm, λ 
EM=340 nm), using bovine serum albumin as the standard. 
RESULTS 
The level of ODC following Sellotape* stripping in the sites treated with flufenamic acid 
averaged 89 ± SE 8 pmol/min/mg protein. This was not significantly different from the 
areas treated with vehicle only, which averaged 100 ± SE 16 pmol/min/mg protein, or 
from the untreated Sellotape-stripped sites, which averaged 110 ± SE 21 pmol/min/mg 
(P>0.05 in both cases, according to the Wilcoxon ranking test). 
UVB irradiation was used to stimulate the induction of ODC; this experiment was 
performed to rule out the possibility that an intact stratum comeum might be required to 
provide a reservoir of flufenamic acid during the induction period. The average level of 
ODC following UVB-irradiation and flufenamic acid treatment was 13.6 ± SE 1.3 
pmol/min/mg protein. This was again not significantly different from the areas treated with 
UVB plus vehicle, which was 12.8 ± SE 3.1 pmoVmin/mg protein (P>0.05). However, 
application of flufenamic acid resulted in a clear reduction of erythema in all six subjects 
compared with UVB plus vehicle or UVB only. There is a significant difference between 
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the average ODC levels of the cream-treated sites and the untreated UVB-irradiated sites, 
which was 22.9 ± SE 3.4 pmol/min/mg protein (Wilcoxon : p=O.025). 
All these data are summarized in table I. 
Table I 
Induction 
Tape stripping 
UVB irradiation 
Treatment 
Nothing 
110 ±21 
22.9 ± 3.4 
Vehicle only 
100 ± 16 
12.8 ± 3.1 
Fluf.ac.3 % 
89 ±8 
13.6 ± 1.3 
Legend to table I 
Mean ODC activities, expressed in pmol/min/mg protein (+ SEM), 8 h after tape stripping 
or UV-B irradiation of none-, vehicle- or flufenamic acid-treated human epidermis. 
DISCUSSION 
During the last few years it has become clear that the response of the skin to Sellotape" 
stripping,1,2 UVB irradiation,3·4 experimental application of TPA5·6 and the clinical 
manifestations of chronic inflammatory diseases such as psoriasis,22 are all mediated by 
activation of the enzyme PKC. This enzyme has many functions, at least two of which are 
well-documented. First, it is responsible for initiation of the arachidonic acid (AA) cascade 
(at least in part by phosphorylation of the PLA2 inhibiting lipocortin)23 and thus the 
synthesis of prostaglandins and leukorrienes. Secondly, it activates the transcription factor 
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API, inducing the synthesis of many of the proteins required for cell division, such as 
ODC.24 This relatively simple model has been made more complicated by the reports that 
ΛΑ products are essential for ODC activation, suggesting that there is cross-talk between 
these pathways. 
We have previous established that, at least in human skin, prostaglandins are not 
required for the activation of 0DC.1S Since the present data make it clear that 
lipoxygenase products play no role in ODC induction either, we have reached the 
conclusion that (at least in the human) this cross-talk does not occur. Two possible 
limitations must be considered. Firstly, the stripping procedure removes the stratum 
corneum which acts as a 'reservoir' for topical drugs. This may be disregarded since the 
experiment with UVB irradiation also gave negative results. The clear reduction of 
erythema on the UVB-irradiated and flufenamic acid treated sites, also reported in animal 
studies,18 confirms bio-availability of the flufenamic acid and demonstrates that AA 
metabolism is indeed suppressed. Secondly, the reduction of ODC levels following UVB 
irradiation and application of vehicle with flufenamic acid or vehicle alone, compared with 
untreated UVB irradiated sites, is of interest. A speculative explanation would be that 
application of any cream or ointment onto the stratum comeum improves the bio­
availability of free sphingosine in human epidermis.25 
The apparent discrepancy between human epidermis and that of rodents in the 
requirements for the activation of proteins such as ODC is surprising, since, in general, 
signal transduction mechanisms such as this are highly conserved throughout evolution. 
Comparative studies using parallel techniques are clearly indicated. 
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Chapter Г 
INHIBITION OF EPIDERMAL ODC 
INDUCTION BY LIGANDS OF THE 
STEROID HORMONE RECEPTOR 
SUPERFAMILY 

4.1 THE INDUCTION OF EPIDERMAL ODC FOLLOWING TAPE 
STRIPPING IS INHIBITED BY A TOPICAL VITAMIN D3 
ANALOGUE (MC903) 
W.P. Arnold, P.CM. van de Kerkhof 
This work was presented at the 18th World Congress of Dermatology, New York, 
June 12* - 18*. 1992 
Topical application of vitamin D3 derivatives has been shown to be effective in 
the treatment of psoriasis. Interference with the state of epidermal 
hyperproliferation has been suggested to be a major target for the action of 
vitamin D3 analogues. In this respect ornithine decarboxylase (ODC) is an enzyme 
with a key role in epidermal homeostasis. 
The aim of the present study was to investigate the effect of MC903, a 
vitamin D3 analogue, on ODC levels in the psoriatic lesion as a state of 
hyperproliferation and to examine its influence on the induction of 
hyperproliferation by tape stripping. 
In total IS patients with chronic plaque psoriasis were treated in a double 
blind approach with MC903 in two different cream bases or a placebo cream. In 
addition to lesionai skin a test area of uninvolved skin was treated with the cream 
twice daily. Keratotome biopsies were taken from the lesions before and after 8 
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weeks treatment and from the stripped areas, pretreated and untreated symptomless 
skin. 
Although ODC activity within the MC903 treated lesions remained 
unaffected, the trauma induced induction of ODC activity proved to be profoundly 
inhibited by MC903. The observation that this vitamin D3 analogue inhibits the 
induction of ODC in vivo lends further support to the hypothesis that the steroid 
receptor superfamily is of general relevance for epidermal proliferation control in 
humans. 
INTRODUCTION 
The skin is the site for the synthesis of vitamin D and moreover a target tissue for 
its active metabolite, l,25-(OH)2 D3. This hormone inhibits proliferation and 
induces terminal differentiation of the epidermis in vitro and in vivo, (reviewed by 
Holick) Therefore topical and oral administration of l,25-(OH)2 D3 have been 
used successfully for the treatment of psoriasis, a hyperproliferative skin disorder 
with incomplete differentiation. 
l,25-(OH)2 D3 is also a calcium regulating hormone, so its administration 
may result in development of hypercalcaemia and hypercalciuria. MC903 is a 
novel 1Д5-(ОН)2 D3 analogue which is as potent as l,25-(OH)2 D3 in the 
epidermis, but is at least 100 times less active in its effects on calcium 
121 
metabolism. MC903 in an ointment base has proven to be an effective and safe 
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treatment for psoriasis in several double-blind studies. [3,4,5] 
Ornithine decarboxylase (ODQ is a rate-limiting enzyme for polyamine 
biosynthesis. Polyamines are required before DNA synthesis can begin, thus ODC 
is an appropriate "marker enzyme" for cellular proliferation. In normal 
epidermis ODC levels are undetectable, but ODC induction has been demonstrated 
following injury (tape stripping , UV-radiation 0 and application of tumor 
[9] 
promoting agents. Stripping of human epidermis in vivo causes an ODC peak at 
8 h. Several groups have reported increased ODC levels in the lesions of 
psoriasis, and have shown that these normalize following therapy (reviewed by 
Lowe).[11] 
l,25-(OH)2 D3 as well has proven to inhibit the ODC induction in the 
[12 13] 
epidermis of rodents, ' but to the best of our knowledge not yet in human 
epidermis. Therefore the aim of the present study was to investigate the effect of 
MC903 on ODC levels in the psoriatic lesion as a state of chronic 
hyperproliferation, and to examine its influence on the induction of 
hyperproliferation by tape stripping. 
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MATERIALS & METHODS 
Subjects and treatment protocol 
Fifteen patients with chronic plaque psoriasis (8 M, 7 F; age range 18-75, mean 
39 year) collaborated for 10 weeks in a double blind study to evaluate the efficacy 
of two different MC903 cream formulations, as part of a large European study 
undertaken by Leo Pharmaceutical Products, Denmark. In cream "A" MC903 was 
dissolved with an emulgator and in cream "B" MC903 was suspended as fine 
particles, both at 50 pg/g. 
All patients underwent a preliminary "wash out" period of 2 weeks 
(treatment of the lesions with an indifferent cream). Six patients were randomly 
allocated a supply of cream A, 6 of cream В and three the placebo. The cream 
was applied to all lesions (other than those on the scalp, face or anogenital region) 
twice daily for a period of 8 weeks. No other antipsoriatic therapy was permitted, 
except for the localizations mentioned above. 
Blood samples for analysis of Hb, RBC, WBC, platelets, bilirubin (total), 
alkaline phosphatase, alanine aminotransferase, creatinine, calcium (total), albumin 
and phosphate were taken after 0, 2 and 8 weeks treatment. 
Skin sampling and Sellotape stripping 
Epidermal slices of approximately 1 cm2 were taken from the centre of a lesion on 
the right elbow on the first and last day of the MC903 treatment Biopsies were 
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cut from sites still showing some psoriatic activity. For this we used a Castroviejo 
keratotome (Storz Instr. Co.) set for a depth of 0.3 mm. 
In addition, the patients were asked to apply the cream on an uninvolved 
area of 5 cm2 of their left upper arm in the last 3 weeks. On the last day this 
treated uninvolved area and the opposite untreated area on the right arm were 
stripped with SellotapeR as described previously. After 8 h a keratotome biopsy 
was taken from both sites. All biopsies were snapfrozen in liquid nitrogen and 
stored at -80°C prior to analysis. 
ODC and protein measurement 
Measurement of ornithine decarboxylase and soluble protein was done as 
described previously. In brief, shave biopsies were homogenised in buffer and 
14 
aliquots were incubated at 37°C after adding L-[l- C]-ornithine. Each tube was 
fitted with a plastic cap carrying a filter paper moistened with KOH. The reaction 
14 
was stopped with Hcl, again incubated and CO2 in the paper was measured. 
Soluble protein was determined in the clear supernatant by direct fluorescence. 
Statistical analysis 
Analysis of variance was carried out for treated and untreated skin using 
the SAS package (t-test for paired data) and a VAX computer system. 
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RESULTS 
Treatment with MC903 cream for 8 weeks caused virtual clearing in three 
patients, five patients showed a moderate reduction of their lesions and in three 
patients the lesions remained in a steady state. One patient dropped out due to the 
use of a solarium in the trial period. In the placebo group (n=3) all psoriatic 
lesions extended. No pathological changes with respect to haematology and blood 
chemistry were seen during the trial period. These data will be included in the 
joint European Study to be reported in full by Leo Pharmaceutical Products in due 
course. 
In the ODC assay the reagent blank (including instrument background) 
averaged about 22 cpm; total reaction samples were between 60 and 950 cpm. The 
assay was linear with respect to time for about 45 min, so an incubation period of 
45 min was used for routine measurements. The reproducibility was good, 
duplicate assays averaging within ± 4.1% of the mean. 
In the psoriatic lesion ODC levels before treatment (n=13) were 2.6 ± 0.7 
pmol/min/mg protein (mean ± SEM). This is in agreement with a previous report 
of Russell et al., who found ODC levels of 2.7 pmol/min/mg protein. ODC 
levels after treatment with MC903 (n=ll) in creams A and В were 3.1 ± 1.3 and 
2.4 ± 0.6 pmol/min/mg protein, respectively. ODC values after placebo treatment 
(n=2) were 3.2 and 6.2 pmol/min/mg protein. Thus the present study did not show 
any downward regulation of ODC to basal (undetectable) levels. 
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In the uninvolved untreated skin ODC levels 8 hours after stripping were 
58.6 ± 12.6 pmol/min/mg protein (n=ll). These values are in line with our 
previous observations. MC903 treatment (n=9) resulted in a substantial 
reduction, reaching 26.6 ± 6.8 in the cream A group (p = 0.06) and 17.3 ± 3.4 
pmol/min/mg protein in the cream В group (p = 0.07). Pooling of all treated 
samples yields a value of 22.5 + 4.2 pmol/min/mg protein, showing a highly 
significant difference from the controls (p=0.004). ODC values after placebo 
treatment (n=2) were 137.2 and 80.4 pmol/min/mg protein, excluding any base 
influence. 
DISCUSSION 
Although MC903 treatment resulted in a clinical improvement of 8 out of 11 
patients, pretreatment and posttreatment ODC levels were comparable. In contrast, 
MC903 treatment of uninvolved skin resulted in a pronounced inhibition of the 
induction of ODC following standardized injury. 
MC903 has proven to inhibit DNA synthesis, * to reduce the amount of 
keratin 16, a marker for hyperproliferation, ' and to reduce the number of 
cycling cells indicated by nuclear staining of КІ67 (antigen expressed only in 
[181 dividing cells). Therefore the dissociation between clinical resolution and ODC 
levels in the psoriatic lesion during MC903 treatment is intriguing. It is feasible 
that other mechanisms are involved in the resolution of established 
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hypeiprolìferatìon in the chronic plaque. In this respect it is of interest that 
interference with inflammation control i.e. disappearance of polymorphonuclear 
[18] 
leucocytes has been observed after 1 week's treatment with MC903. On the 
other hand ODC might be an indicator for "complete" healing. 
Trauma-induced hyperproliferation is an acute event; 8 h after trauma there 
is a maximal ODC induction and 48 h later the percentage cells in the SG2M-
[14] 
phase reaches maximum levels. As such this model is appropriate to study the 
induction of hyperproliferation in the epidermis. Remarkably this induction is 
blocked profoundly by MC903, which supports the hypothesis that the steroid 
receptor superfamily is of relevance for the control of epidermal homeostasis. 
Members of this family are for example the glucocorticoid-, thyroid hormone-, 
retinoic acid- and vitamin D- receptors. In their inactive state they are thought to 
be bound to an inhibitor protein that blocks the DNA-binding domain of the 
receptor. The binding of hormone to the receptor causes the inhibitor protein to 
dissociate, thereby activating the receptor. The receptor in turn is then capable of 
blocking or stimulating an enhancer/promoter region before or after a coding 
[19] DNA-sequence, for example for ODC-mRNA. However, evidence has very 
recently been presented for an alternative concept The phosphorylated c-jun/c-
fos product (AP-1), which is responsible for activation of the ODC-promoter, 
complexes with and is blocked by the activated corticosteroid receptor. 
[21] In this way glucocorticoids block the ODC induction in the epidermis' thyroid 
[22] 
hormone stimulates the proliferation of epidermal cells, probably via ODC 
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' retinóte acid inhibits the ODC induction in the skin and vitamin 
D3 blocks the epidemial ODC induction as well. 
The present study demonstrates the in vivo relevance of a vitamin D3 
analogue on epidermal growth control of human skin. As l,25-(OH)2 D3 has been 
[24] 
shown to inhibit ODC induction at the gene transcript level, it is worthwhile to 
further elucidate this mechanism in genetic terms. 
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4.2 THE INDUCTION OF EPIDERMAL ODC FOLLOWING UV-B 
IRRADIATION IS INHIBITED BY ESTRIOL 
W.P. Arnold, B.J.H. Pennings, P.C.M. van de Kerkhof 
This work was presented at the 23"1 annual meeting of the E.S.D.R., Amsterdam, April 
3 r d .
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The induction of epidermal ornithine decarboxylase (ODC) can be partially blocked by 
corticosteroids, retinoic acid or active vitamin D3. The influence of the other members of 
this so-called "steroid hormone receptor superfamily" (SHRS), namely the sex-steroids and 
thyroid hormone, is unknown in epidermis, but they enhance ODC induction in certain 
other tissues. 
Here we investigated whether topical estriol leads to a spontaneous and/or 
enhanced epidermal ODC induction 8 h after UV-B irradiation of 6 postmenopausal 
women. Contrary to expectation, estriol did not stimulate induction, but reduced induction 
by 44%. This observation raises the possibility that all members of the SHRS may share a 
common AP-1 binding site. 
INTRODUCTION 
Ornithine decarboxylase (ODC) is the rate-limiting enzyme in the production of 
75 
polyamines, which are essential for DNA duplication. Hence, ODC is used as "marker-
enzyme" for proliferation. Under physiological circumstances epidermal ODC is 
biochemically not detectable, but can be induced following standardized injuries such as 
tape stripping of the stratum corneum (activity peak after 8 h)1 or irradiation with UV-B 
(peak after 24 h).2 This induction can be partially blocked by certain members of the so-
called "steroid hormone receptor superfamily", namely corticosteroids,1 retinoic acid3 and 
active vitamin D3.4 The influence of other members, the sex-steroids (progesterone, 
estrogens, testosterone) and thyroid hormone has not yet been investigated in the 
epidermis, although they enhance ODC induction is other tissues.3-6,7 Since corticosteroids, 
retinoic acid and calcipotriol are potent antipsoriatic drugs, it seems worthwhile to study 
the effects of the other members of this superfamily on epidermal ODC induction. 
Human keratinocytes contain estrogen receptors in varying concentrations, 
apparently depending on location and age.8·'·10 However, exact information is not available 
due to limitations in detection techniques. In the epidermis estrogens have once been 
reported to increase the mitotic rate,11 but this single early report has remained 
unconfirmed. They have negative effects on epidermal adnexal structures, i.e. by reducing 
the size and activity of sebaceous glands12 and the rate of hair growth." In the dermis 
estrogens stimulate the synthesis, maturation and turn over of collagen,14 increase the 
synthesis of hyaluronic acid13 and increase the vascularization.16 
Here we have addressed the following question: Does topical application of estriol 
lead to a spontaneous and/or enhanced induction of ODC in human epidermis in vivo! 
ODC measurements were carried out in vehicle- and estriol-treated epidermis 8 h after 
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irradiation with UV-B, when ODC activity is still suboptimal, and in estriol treated 
epidermis only. 
METHODS 
Subjects Six postmenopausal women (age range 57-69 years) without estrogen substitution 
therapy (tablets, plasters or vaginal creams) and without a previous history or signs of 
uterineVbreastcancer, liver pathology or thrombo-embolic processes participated in this 
project. Every woman had skin type II or Ш. Informed consent was obtained from all the 
subjects and the study had the approval of the Medical Ethics Committee. 
The minimal erythema dose (MED) for each individual was determined and two 
sites on their backs (3 cm2) were each irradiated with 3 MEDs of UV-B according to 
MacKenzie. Immediately after irradiation the left site was treated with 200 mg crémor 
lanette (per g: lanette wax cream 150 mg, cetiol 200 mg, sorbitol in water), the right side 
with the same amount of estriol (Sigma) in crémor lanette (1 mg/g) and this estriol cream 
was also applied on an unirradiated site on the right side. All three areas were occluded 
with a non-toxic plastic foil for 8 h. After this period the skin was cleaned with 70% 
ethanol and biopsies (approximately 1 cm2) were taken from the centre of each site using a 
Castroviejo keratotome (Storz) under local anaesthesia produced by cooling the skin with 
ethyl chloride. Biopsies were washed briefly in cold phosphate buffered saline and snap 
frozen in liquid nitrogen prior to analysis. 
ODC and protein measurements These have been described previously;1 the ODC assay 
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was modified by reducing the amount of "cold" ornithine in the reaction mixture from 40 
nmol to 4 nmol to improve the sensitivity. 
Statistics The Wilcoxon signed-ranks test for matched pairs (two-tailed) was used for 
statistical analysis. 
RESULTS 
Although all women received the standardized dose of 3 MED of UV-B, the range of 
ODC induction varied from 8 to 65 pmol/min/mg protein, as shown in Table I. These 
findings were in accordance with previous observations that an increase in age is 
accompanied with an increased spread in individual values (unpublished data). Therefore 
we normalized all ODC activities to 100% (see Table I, col. 6). 
At the time of biopsy no differences in erythema were visible in the vehicle- and estriol-
treated irradiated areas. Nevertheless, as seen in Table I, ODC activities in the estriol-
treated irradiated sites of all six women were lower than the vehicle-treated irradiated 
areas, averaging 56% + 10% (mean + SEM; р=Ю.ОЗ) of this control, almost in accordance 
with the effects of a potent corticosteroidi!]. ODC activities in the estriol-treated sites 
without irradiation were not detectable in any of the 6 samples. 
LEGEND TO TABLE I 
ODC levels following UVB only, UVB plus estriol and estriol only. The figures in col. 6 
7R 
are calculated as (col. 4/col. 3) xl00%. 
Subject 
No 
1 
2 
3 
4 
5 
6 
Mean 
SEM 
Age 
69 
63 
62 
57 
60 
62 
62 
1.6 
- - .-
ODC (pmol/min/mg protein) 
UV-B 
only 
08 
17 
49 
38 
65 
29 
34 
8.5 
UV-B + 
estriol 
03 
05 
34 
31 
55 
10 
23 
8.4 
estriol 
only 
< 1 
< 1 
< 1 
<1 
< 1 
< 1 
< 1 
Effect of 
estriol 
38% 
29% 
69% 
82% I 
85% 
34% 
56% 
10% 
DISCUSSION 
It is clear from our results that topical application of estriol does not lead to a spontaneous 
or enhanced induction of ODC in human epidermis in vivo. On the contrary, this member 
of the steroid hormone receptor superfamily seems to share the capacity to antagonize 
ODC transcription with its corticosteroid-, retinole acid- and vitamin D3-relatives. 
Activated corticosteroid receptors reduce ODC induction by formation of a 
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heterodimer with the ODC-transcription factor AP-1,17 probably subsequent to binding 
onto their specific response elements immediately upstream of the coding region of the 
DNA. Similar mechanisms are thought to be responsible for ODC inhibition by retinoic 
acid and vitamin D3.18 Could it be that this AP-1 binding site already existed in the 
phylogenetically oldest steroid receptor molecule and has remained constant during 
evolution, adding new hormone- and DNA-binding regions at different sites?19 But how 
could the opposite effects of estrogen on ODC induction in epidermis as compared to 
other tissues be explained? An explanation may be that in these latter tissues ODC 
transcription is directly regulated by the activated estrogen-receptor, without participation 
of the c-jun/c-fos complex. 
Much research still has to be done. For example, it would obviously be of value to 
quantify and characterize estrogen binding sites; unfortunately using current techniques 
this requires more material than can conveniently be obtained from biopsies. Secondly, 
modern flowcytometric methodology offers the possibility to re-investigate the early claim 
regarding the influence of estrogens on epidermal cell cycle kinetics. Finally, localization, 
isolation and synthesis of this common AP-1 binding site, may eventually lead to a 
strongly antiproliferative drug without hormonal side-effects. 
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Chapter V 
ODC AS MARKER ENZYME TO TEST 
(NEW) ΑΝΤΙ-PSORIATIC THERAPIES 

5.1 EFFECTS OF SPHINGOSINE, ISOQUINOLINE AND TANNIC ACID ON 
THE HUMAN TAPE-STRIPPING MODEL AND THE PSORIATIC LESION 
W.P. Arnold, СР. Glade, P.D. Mier, P.C.M, van de Kerkhof 
Parts of this work were presented at the 22nd annual meeting of the E.S.D.R., London, 
April 4tt - 7Ш, 1992 
Published data (mainly from rodent skin) suggest a correlation between compounds which 
inhibit protein kinase С (PKC), have anti-inflammatory or anti-tumour promoting 
characteristics and possess antipsoriatic potential. Here we have investigated the effects of 
topical application of sphingosine (Sph; a naturally occurring PKC-inhibitor), isoquinoline 
(IQ; a component of coal tar which showed antipsoriatic capacities in the mouse tail 
model) and tannic acid (TA; a plant phenol with anti-tumour promoting activity) to human 
skin. In each case we have assessed a) the level of induction of ornithine decarboxylase 
(ODC) following SellotapeR-stripping as an indicator for potential PKC inhibition in vivo, 
and b) its effects on the lesions of chronic plaque psoriasis. 
The control group consisted of 18 healthy volunteers, used for the ODC induction 
experiments (0.0/0.1/0.2M Sph in ethanol, 100% coal tar and 0/50mM TA in acetone) and 
17 psoriatic patients used for double-blind scoring of two randomly selected lesions 
(0.0/0. IM Sph in ethanol, 0.0/0.2% IQ in white vaseline / lanette wax cream 50%/50% 
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and 0/10% TA in lanette wax cream) and also for certain of the ODC induction 
experiments (0.0/0.2% IQ and 0/10% TA). Biopsies were taken 8 h after stripping and 
ODC activity was assessed by measurement of MC0 2 release. Lesions were scored with a 
modified Psoriasis Area and Severity Index on days 0, 7 GQ and TA), 13 (Sph) and 21 
(IQ and TA). 
Application of 0.1M or 0.2M Sph resulted in a decrease of ODC activity of 52 % 
and 66 % respectively (p < 0.01), but histologic sections showed intra-epidermal necrosis. 
IQ, coal tar and TA did not have any significant influence on ODC induction (p > 0.05). 
All compounds failed to show significant improvement of the psoriatic lesions. Therefore 
we may conclude that 'theoretical' anti-psoriatic agents may be limited in practice by 
cytotoxicity and hence a narrow therapeutic index, poor penetration and lack of specificity. 
Further, a marked difference between the effects of these compounds on the skin of 
different species increases the difficulty of predicting antipsoriatic activity. 
INTRODUCTION 
Protein kinase С (PKC) is a calcium- and phospholipid-dependent serine/threonine kinase 
of central importance in the signal transduction pathways which mediate cellular responses 
to inflammatory stimuli.'11 It is immediately downstream to the phosphotidylinositol cycle, 
being activated by diacylglycerol and Ca2*. PKC in turn mediates a number of subsequent 
events, including initiation of the arachidonic acid cascade, phosphorylation of the NaVH* 
pump and the induction of many gene products (such as the enzyme ornithine 
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decarboxylase, ODC14) via activation of the transcription factor AP-l.m It has become 
clear that activation of PKC is necessary for the recruitment of quiescent keratinocytes 
into the cell cycle/41 and there is strong evidence that it is chronically over-stimulated in 
the lesions of psoriasis.[51 Experimentally, PKC is activated by phorbol esters such as 12-
O-tetradecanoylphorbol-13-acetate (TPA); topical application of these compounds causes 
an acute inflammatory response and, following repeated application, results in tumour 
promotion."·21 
The foregoing data would lead us to expect some correlation between the ability of 
a compound to inhibit PKC, anti-inflammatory or cytostatic working, anti-tumour 
promotion characteristics and antipsoriatic potential. In fact, a number of compounds have 
been reported in which at least two of these effects have been described; for example the 
well-known antipsoriatic agent dithranol has recently been reported to be a potent PKC 
inhibitor.16' However, little systematic work has been carried out along these lines. Further, 
the available data are obscured by uncertainties regarding species differences; this problem 
is exacerbated by the fact that no reliable animal model is available for psoriasis, and the 
experimental application of many chemical substances (especially TP A) to human skin is 
ethically unwarranted. 
In this report we have investigated the effect of topical application of three 
compounds to human skin, which are either established PKC inhibitors or known anti-
tumour promoters. These substances were sphingosine171 (a naturally occurring lipid-
metabolite[8],which direct absorption has been demonstrated in intact mouse-skin), 
isoquinoline19'101 (0.2% present in the therapeutically accepted agent coal tar1111) and tannic 
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acid[12' (earlier used, for example, following burns1"1). In each case we have assessed a) 
the level of ODC induction following Sellotape* stripping1141 as an indicator for potential 
PKC inhibition in vivo, and b) its effect on the lesions of chronic plaque psoriasis. 
METHODS 
Subjects 
The control group consisted of 18 paid volunteers (6 male, 12 female; age range 18-57 
years, mean 28 years) without signs or history of skin diseases. Areas on their back were 
treated as described in the treatment protocols; sub-group numbers are given in table I. 
The psoriatic group comprised 17 paid patients (11 male, 6 female; age range 29-
64 years, mean 44 years) with chronic plaque psoriasis, who had received no oral/topical 
therapy for at least 4/2 weeks prior to investigation respectively. In each patient two 
symmetrical, comparable lesions were selected at a distance of at least 5 cm from other 
psoriatic areas. Lesions were treated as described in the treatment-protocols and scored 
double-blind with a modified Psoriasis Area and Severity Index (mPASI) : [E + I + D] 
χ (0 /0 ). E=erythema, I=infiltration, D=desquamation; severity scale 0-4, t = time-
point of scoring, χ = duration of treatment (days) and 0 = biggest measurable crosssection 
(cm). Scoring-days and sub-group numbers are given in table Π. 
The use of UV-B sources or vitamin A/D tablets was specifically excluded in all 
subjects immediately prior to or during the experiments. Informed consent was obtained 
from all subjects and the study had the approval of the Medical Ethics Committee. 
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Sphingosine Treatment Protocol 
Volunteers. Three sites of 1.75 cm2 each were marked and 35 μΐ solution of 0.2 M and 0.1 
M sphingosine (Sigma) in ethanol and ethanol only were applied through a plastic 
cylinder. The ethanol was evaporated with air under pressure. The sites were then 
occluded for 30 min with a non-toxic plastic foil. Tape stripping was carried out, 
immediately followed by a second application of 35 μΐ sphingosine of the same 
concentrations. After being covered with a gauze for 8 h, biopsies were cut from each site. 
Ethanol only and 0.2 M sphingosine were applied to the backs of 2 volunteers 
following the same procedure as described above. Razor blade biopsies were taken 8 h 
after tape stripping. Paraffin tissue sections were stained with H & E. 
Patients. Using a within subject left-right comparison one lesion was treated with 0.1 M 
sphingosine and the contralateral lesion with ethanol only. Volumes of 20pl/cm2 were 
applied twice a day for 12 days and the treated areas were covered with a gauze. 
Isoquinoline/Coal Tar Treatment Protocol 
Volunteers. Crude coal tar (GEM Pharma) containing 0.2% isoquinoline, was applied in an 
area of 3 cm2 and covered with a gauze. This area and a contralateral site were tape 
stripped after 16 h, immediately followed by a second application of the coal tar on this 
first area, which was again covered with a gauze. A biopsy was taken from both sites after 
8 h. Additionally 2 volunteers underwent the same treatment protocol as for the 
uninvolved skin of the psoriatic patients, i.e. twice daily applications of coal tar for one 
week, before tape-stripping and biopsy. 
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Patients. On day 0 two jars with cream were supplied; one jar contained vaseline album / 
lanette wax cream 50% / 50% with 0.2% isoquinoline (Sigma) and the other jar the 
basecream only. The jars were randomly allocated to "left" or "right" and the patients were 
asked to use the cream according this division on their left or right lesion twice daily. In 
their last trial week the patients started applying the creams also twice daily on 2 
uninvolved areas of ± 3 cm2 at least 10 cm away from the treated lesion. On day 21 these 
areas were tape stripped, immediately followed by application of the corresponding cream, 
occlusion with a gauze and after 8 h a biopsy from each site was taken. 
Tannic Acid Treatment Protocol 
Volunteers. Thirty pi of 50 mM tannic acid (Sigma) in acetone and acetone only were 
applied on 2 areas of 1.75 cm2, evaporated with air under pressure and occluded with a 
non-toxic plastic foil. Tape stripping of these areas was carried out after 1 h. Immediately 
after this procedure 30 ul of the same solution was applied to these sites, which were left 
under occlusion with a non-toxic foil for 8 h. Biopsies were then taken. 
Patients. On day 0 two jars were supplied; one jar contained lanette wax cream with 10% 
tannic acid and the other jar lanette wax cream only. The jars were randomly allocated to 
"left" or "right", following the same treatment protocol as for isoquinoline. 
Tape Stripping & Biopsies 
After cleaning the skin with 70% ethanol (in the cream-experiments only), SellotapeR 
stripping was done as described previously,1141 using a plastic template to restrict the 
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damage to the pre-treated areas only. A biopsy of approximately 1 cm2 was cut from each 
site, using a Castroviejo Keratotome (Storz) set for a depth of 0.2 mm after cooling the 
skin with an ethyl chloride spray. Biopsies were washed briefly in ice-cold phosphate-
buffered saline and snap frozen in liquid nitrogen prior to further analysis. 
ODC & Protein Measurement 
Measurements of ODC activity and soluble protein levels were carried out as previously 
described.1141 Biopsies were homogenized in buffer (0°C) and aliquots incubated at 37°C 
after adding L-(l-,4C)-ornithine (NEN). Each tube was fitted with a plastic cap carrying a 
filter paper moistened with potassium hydroxide; the reaction was stopped with 
hydrochloric acid, incubated again and 14C02 was measured. Soluble protein was 
determined in the clear supernatant by direct fluorescence (λρ =280nm, Xp=340nm). 
Statistical Analysis 
Analysis of variance was carried out for treated and untreated skin using the SAS package 
(t-test for paired data) and a VAX computer system. 
RESULTS 
Induction of ODC 
Table I gives an overview on the effects of sphingosine, isoquinoline and tannic acid on 
epidermal ODC induction. Application of 0.1 M or 0.2 M sphingosine resulted in a 
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decrease of ODC activity of 52% and 66% respectively. This effect was significantly 
different compared to ethanol only (p<0.01); there was no significant difference between 
application of 0.1 or 0.2 M sphingosine (Duncan's multiple range test, a=0.05). However, 
at a macroscopical level, there was both subjective (mild burning sensation) and objective 
(spreading erythema) evidence of a marked dose-dependent irritant effect of sphingosine. 
Application of 0.2% isoquinoline or even crude coal tar did not have any significant 
influence on ODC induction (p>0.05 in both groups). These coal tar results were not 
altered by increasing the treatment period (n=2). The activity of ODC was also neither 
altered significantly by 10% or 50 mM tannic acid (p>0.05 in both groups) compared to 
basecream or acetone respectively. The substantial differences of ODC values in those two 
groups are presumably due to the use of occlusion in the latter, since increased 
temperature and humidity enhance wound-healing. 
Agent 
Sphingosine 
Isoquinoline 
Coaltar 
I 
[...] 
0.1M 
0.2M 
0.2% 
100% 
1 
η 
7 
7 
7 
6 
ODC activity in 
treated area 
30 ± 8 
21 ± 4 
116 ± 18 
91 ±27 
ODC activity in 
base-treated area 
62 ± 6 
62 ± 6 
113 ± 35 
115 ±20 
1 
Ρ 1 
<0.01 
<0.01 
>0.05 
>0.05 
Tannic acid 10% 
50mM 
6 
4 
71 ± 17 
176 ± 40 
71 ± 7 
131 ± 28 
>0.05 
>0.05 
Table I ODC activities, expressed as pmol/min/mg protein (mean ± SEM), 8 h after 
tape stripping of (pre-)treated skin. 
Histology 
The histologic sections from the volunteers treated with ethanol only showed minor PMN 
infiltration 8h after tape stripping, with all epidermal layers (excluding the str. corneum) 
and the underlying tissue being completely undamaged (fig. la). In the 0.2M sphingosine 
treated sections there was a slightly more profuse PMN infiltration with intra-epidermal 
(basal & suprabasal) vesicles filled with a necrotic, amorphous material (Fig.lb). 
1A • 
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Figure 1 Histologie effects of sphingosine on tape-stripped human epidermis. (A) 
Ethanol only 8 h after the second application. (B) Plus 0.2 M sphingosine 8 
h after the second application. Magnification 25x. 
Clinical Trials 
Table Π gives an overview on the effects on sphingosine, isoquinoline and tannic acid on 
the psoriatic lesions. In these concentrations and these véhicula, all compounds failed to 
show significant improvement in this double-blind approach (p>0.05). This was in 
accordance with the negative subjective estimation of the patients. No side-effects of any 
of the drugs or basis were noticed by the physician nor mentioned by the patients. 
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Agent 
Sphingosine 0.1 M 
Ethanol only 
Isoquinoline 0.2% 
Vaseline/Lanette wax cream 
Tannic acid 10% 
Lanette wax cream 
η 
4 
7 
6 
day 0 
7.8 ± 1.0 
7.5 ± 0.9 
5.6 ± 0.8 
5.4 ± 0.6 
5.7 ± 0.7 
5.3 ± 0.7 
day 7 
-
4.1 ± 0.7 
3.2 ± 0.7 
5.2 ± 0.7 
4.0 ± 1.0 
day 13 
5.8 ± 1.0 
6.2 ± 1.6 
-
-
J J 
day 21 
-
2.1 ± 0.3 
2.6 ± 0.7 
3.5 ± 0.6 
4.0 ± 0.6 
Table Π mPASI's (mean ± SEM) of the treated psoriatic lesions. No agent resulted 
in a significant difference compared to its vehiculum at any time (p>0.05). 
DISCUSSION 
Sphingosine 
Three new observations are reported here. First, sphingosine at a concentration of 0.1 M or 
0.2 M blocks the induction of ODC following tape stripping of human skin. Second, at 
this concentration there is evidence of a marked irritant effect both at the macroscopical 
(0.1 M and 0.2 M) and at the histological (0.2M) levels. Finally, 0.1 M sphingosine fails 
to show a significant effect on the psoriatic lesion. 
The effects of sphingosine on ODC induction are compatible with those reported 
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by Gupta et al.1 ' and Enkvetchakul et al.,'1 ] using TPA-stimulated mouse skin. 
Surprisingly however, neither group mentions cytotoxicity. This contrast suggests that the 
loss of barrier function resulting from stripping permits cytotoxic concentrations of 
sphingosine to reach the viable cell layers. But our preliminary experiments with 0.01 M 
and 0.02 M sphingosine failed to show inhibitory effects on ODC induction, so the range 
between PKC inhibition causing cellular effects and PKC inhibition causing cytotoxicity is 
extremely small. This finding is in line with data regarding various PKC inhibitors in cell 
culture experiments."6' Whether this small range will diminish the therapeutic potential of 
PKC inhibitors in psoriasis, remains an open question for the future. Another question 
concerns the methodological distinguishment between inhibition of the induction or direct 
inhibition of ODC activity by sphingosine. However, no report of direct effect of 
sphingosine on enzymatic activity of ODC has ever been published. 
It may be noted that sphingosine reduced ODC levels following stripping from ± 
60 to ± 30 pmol/min/mg protein. Since reported ODC activity in untreated psoriatic 
lesions is around 3 pmol/min/mg protein"7', one may assume that sufficient activity 
remains to support this increased proliferation rate. One may also assume that the irritant 
effect of sphingosine is counteracting any therapeutic effect induced by inhibition of ODC. 
However, the situation seems extremely similar to that of dithranol, since in fact (a) both 
are irritants, (b) both inhibit PKC'6' and (c) dithranol reduces proliferation'18'. The precise 
relationship between these observations is still unclear, but - as we know for dithranol -
does not exclude a useful antipsoriatic effect. 
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Isoquinoline 
Although in itself not known to have inhibitory effects on PKC, derivatives of 
isoquinoline191 surely do. Additionally, isoquinoline is a component of coal tar (a potent 
anti-psoriatic agent), that promised anti-psoriatic capacities in the mouse tail model.'10' 
Therefore we tested both isoquinoline and coal tar for their effects on epidermal ODC 
induction (for practical reasons in psoriatic uninvolved and healthy epidermis respectively, 
since ODC induction does not differ between psoriatics and healthy controls"41) and 
isoquinoline only for anti-psoriatic potential. 
Of the common negative findings, the coal tar results are especially remarkable. 
Almost all anti-psoriatic therapies (corticosteroids, retinole acid, vitamin Dj) inhibit 
epidermal ODC induction,'171 except the UV-B-'19' and dithranol- (unpublished data) 
treatments, that induce ODC per se. This study shows that one of the most efficient anti-
psoriatic therapies, 100% crude coal tar, neither inhibits nor induces ODC. How all these 
different therapeutical approaches intervening in various ways in the disturbed triangle 
proliferation-inflammation-differentiation finally lead to the same nett result, remains one 
of the most intriguing questions in psoriasis. 
Tannic Acid 
The high dosage of 10% tannic acid in a cream base does not have anti-psoriatic 
properties and does not inhibit tape stripping-induced ODC activity in human epidermis in 
vivo. Tannic acid (TA) belongs to the naturally occurring astringents, that precipitate 
proteins but have so little penetrability that only the surface of cells is affected.1201 So our 
97 
negative data are wholly compatible with the extremely low penetrability of the plant 
phenols. Therefore, the value of our experiments with tannic acid lies in the fact, that 
other research-workers have never mentioned the poor absorbance of tannic acid. 
In the past Dutch dermatologists used TA in a cream base as UV-B protector and 
German dermatologists still use TA as an adjuvant in the treatment of skin bums and 
acute dermatitis; in the English dermatological literature TA is not mentioned. In the 
biochemical literature, however, TA is a well-known inhibitor of skin tumor initiation. 
Recently Gali et al.1121 described for the First time its anti-tumour promoting activity. Why 
do our results differ from those of Gali et al.? Differences in the bioavailability of TA 
cannot be the reason, since in the animal model the (smaller) stratum corneum remained in 
situ and in our model the stripping in itself afforded maximal penetration. An explanation 
could therefore be that TA directly reacts with and hence inactivates TPA on the skin 
surface; resolution of this paradox must await further research. 
In summary we may conclude that the experimental demonstration of the correlations 
suggested in the Introduction is limited by a number of practical considerations. These 
include cytotoxicity Grading to a narrow therapeutic index), poor penetration of the 
stratum corneum and probably lack of specificity. A further problem, illustrated by our 
data regarding sphingosine and tannic acid, is the apparently marked difference between 
the effects of these compounds on the skin of different species. It is clear that a great deal 
of further work remains to be done, especially in view of the large number of potent and 
specific inhibitors of PKC, which have recently been isolated16 and which are now 
becoming commercially available. 
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5.2 CYCLOSPORIN A DOES NOT AFFECT EPIDERMAL PROLIFERATION 
FOLLOWING STANDARDIZED INJURY 
W.P. Arnold, M.-J.P. Graritsen, P.C.M. van de Kerkhof 
This work was presented at the 23rd annual meeting of the E.S.D.R., Amsterdam, April 
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Cyclosporin A (CsA) is used in the treatment of severe psoriasis, reducing both 
inflammation and epidermal proliferation.Its targets in the immune system are well 
established, but data regarding possible direct effects on keratinocytes are contradictory. In 
rodent skin, topical CsA blocks the induction of ornithine decarboxylase (ODC), hence 
reducing polyamines essential for proliferation. In psoriatic lesionai skin, however, oral 
CsA does not influence other epidermal proliferation-associated markers. We have now 
assessed ODC activity following standardized injury to psoriatic uninvolved skin, 
combined with nuclear monoclonal binding to Ki-67, a marker for cycling cells, to 
ascertain the in vivo effect of systemic treatment with CsA on epidermal proliferation. 
Ten psoriatic patients were treated with CsA for 16 weeks. Before the start and 
during week 16 two uninvolved areas on their back were tape-stripped in order to induce a 
standardized trauma. Biopsies were taken after 8 h for ODC measurements and after 48 h 
for Ki-67 staining. In contrast to the pronounced influence of CsA on the Psoriasis Area 
and Severity Index, neither parameter was altered significantly by CsA treatment 
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This report excludes indirect inhibitory effects of CsA on protein kinase С (PKQ, 
the key-enzyme in the epidermal proliferation pathway. The question why keratinocytes 
contain a specific receptor for CsA remains unresolved. 
INTRODUCTION 
Cyclosporin A (CsA) is a well known drug in the treatment of severe psoriasis, a skin 
disease characterized by inflammation and epidermal hyperproliferation. It is now well-
established that all known effects of CsA" are, in fact, mediated by the complex of this 
drug with its cellular binding protein, cyclophilin [1]. CsA may affect both inflammation 
and epidermal proliferation. In the T-cell, it has been established that CsA modulates the 
transcription of messenger RNA for interleukin 2 [2-4]. In addition, antigen presentation 
by Langerhans'cells and HLA-Dr expression by psoriatic keratinocytes is inhibited [5,6]. 
On the other hand it has been demonstrated that proliferation of normal human 
keratinocytes is inhibited in culture, although following incubation with concentrations 
considerably in excess of those reached in serum during treatment of psoriatic patients [7]. 
In particular the transition from G0 into G, phase proved to be blocked [8]. In animal skin 
it has been shown that CsA blocked phorbol-ester- and PUVA-induced ornithine 
decarboxylase (ODC) activity [9,10]. ODC is the rate-limiting enzyme in polyamine 
biosynthesis and hence tightly involved in proliferation [11]. Regarding the situation in 
human skin in vivo, does CsA inhibit epidermal proliferation in patients with psoriasis 
during systemic treatment with CsA? 
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As a decrease of epidermal proliferation in the psoriatic plaque obviously might be the 
result of reduction of the inflammatory events in the psoriatic plaques, modulation of 
epidermal proliferation by CsA was studied in an in vivo model. For this purpose we 
investigated the regenerative response following standardized injury by tape stripping, in 
particular the recruitment of cycling cells from the resting G0 population [12]. Ki-67 is a 
monoclonal antibody against a nuclear antigen present in cycling cells [13,14]. Nuclear 
binding with Ki-67 indicates therefore that the cell has passed the transition point from the 
G0 phase into the cycling phase. It has been demonstrated that the activity of ODC is 
directly linked to protein kinase С (PKÇ) activity [IS]. Stimulation and inhibition of PKC 
have been demonstrated to affect accordingly the degree of recruitment of cycling cells in 
the epidermis [16]. Therefore nuclear binding to Ki-67 and ODC activity were assessed in 
the present study to find out the in vivo effect of systemic treatment with CsA on 
epidermal proliferation. 
METHODS 
Subjects 
Ten patients with severe chronic disabling psoriasis (nine male, one female) with a mean 
age of 45 years participated in this study after approval of the Medical Ethics Committee. 
Before entry, patients had not received any oral antipsoriatic therapy for at least two 
weeks and no specific topical treatment for at least one week. All patients started with a 
dose of 3 mg/kg/day of cyclosporin A and depending on the clinical results the dose was 
increased monthly with 1 mg/kg/day to a maximum of 5 mg/kg/day. Every month blood 
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samples were taken to assess plasma CsA levels and to monitor possible side-effects. 
Two days before CsA therapy was started and during week 16 of the CsA treatment, 
SellotapeR stripping was carried out at two 2 cm2 areas of uninvolved skin on their backs. 
By repeated applications of SellotapeR, until the surface becomes glistening, the statum 
comeum is removed completely in order to induce a hyperproliferative response. 
After 8 h, when the induction of ODC activity is maximal [17], a biopsy (1 cm2, 0.2 mm) 
out of one area was taken with a Castroviejo keratotome (Storz Instr. Co., St. Louis, MO, 
USA), immediately snap frozen in liquid nitrogen and stored at -80°C prior to biochemical 
analysis. After 48 h, when epidermal proliferation is most pronounced [18], punch biopsies 
(3 mm diameter) were taken from the remaining area and embedded in Tissue Тек OCT 
compound (Miles Scientific, Napersville, IL, USA), snap frozen in liquid nitrogen and 
stored at -80°C until use. 
ODC and protein measurement 
The measurements of ODC and soluble protein were carried out as described previously 
[17]. Biopsies were homogenized in a specific buffer and aliquots incubated at 37°C after 
adding L-(l-14C)-omithine. Each tube was fitted with a plastic cap carrying a filter paper 
moistened with KOH; the reaction was then stopped with HCl, incubated again and the 
I 4C02 measured. The soluble protein was determined in the clear supernatant by direct 
fluorescence. 
Ki-67 staining procedure 
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Sections of б μιτι were cut, air dried and fixed for 10 min in aceton/ether 60/40 vol%. As 
described before [18], slides were put in a phosphate-buffered stock solution and incubated 
for one hour with the monoclonal antibody Ki-67 (1 : 10, Dakopatts, Copenhagen, 
Denmark). After two bufferwashings the slides were incubated with rabbit anti-mouse 
immunoglobulin conjugated with peroxidase (1 : 25, RAMPO). The slides were washed 
twice again, pre-incubated with sodium acetate buffer (pH 4.9) and a solution of 3-amino-
9-ethylcarbazole containing 0.01% H202 was added for 10 min. This was followed by 
another two washings in demineralized water, before the slides were counterstained with 
Mayers' Haematoxylin (Sigma, St. Louis, MO, USA) and mounted in glycerol gelatin. 
Finally, by microscopical examination, the number of Ki-67 positive nuclei per mm length 
of the section were counted. 
Statistical analysis 
The Wilcoxon signed-ranks test for two-tailed matched pairs (before and after 4 months of 
treatment) was used for statistica! analysis. 
RESULTS 
Values of ODC activities and the number of Ki-67 positive nuclei before the start with 
cyclosporin therapy were within the range of previous findings, excluding possible errors 
in methodology. In contrast to the Psoriasis Area and Severity Index (PASI), neither were 
influenced by the use of cyclosporin; data are summarized in table I. 
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TABLE I 
(η = 10) 
PASI 
ODC 
Ki-67 
Before start of 
cyclosporin 
therapy 
20.5 ± 4.4 
106 ± 32 
104 ±21 
During week 16 
of cyclosporin 
therapy 
4.3 ± 0.6 
125 ± 35 
87 ±19 
ρ values 
<0.01 
>0.05 
> 0.05 | 
Legend to table I 
Mean PASI scores (± SEM) of involved skin compared with mean values (± SEM) of 
ODC activities (pmol.min'.mg protein"1) and number of Ki-67 positive nuclei (per mm 
section length), 8 h and 48 h respectively after tape striping of uninvolved skin, before and 
during cyclosporin therapy. 
DISCUSSION 
Following systemic treatment with CsA at dosages sufficient for a pronounced clinical 
effect, the recruitment of cycling epidermal cells was not affected. Both nuclear binding to 
Ki-67 and ODC activity following tape stripping remained unchanged. 
This in vivo investigation is at variance with the mentioned studies on keratinocytes in 
culture. The discrepancy might be due to a relatively insufficient bioavailability of the 
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drug in the epidermis of our patients. However, the dosages used in these patients were 
sufficient to induce a marked clinical improvement The present observation is compatible 
with the study of Gottlieb et aL [19] who demonstrated that the epidemial proliferation-
associated markers TGFcc, IL 6 and keratin 16 were unaffected by systemic treatment with 
CsA. 
Recently our group has confirmed that cytosolic extracts of human epidermis, and more 
specifically, cultured human keraünocytes contain cyclophilin [20]. Various metabolic 
effects of CsA on epidermis have been shown, for example inhibition of ODC activation 
by phorbol-esters and PUVA irradiation [9,10]. In contrast to these effects, CsA can 
increase the degree of phosphorylation at serine and threonine residues via inhibition of 
protein phosphatase 2B [21], and is thus synergic with PKC. 
Systemic treatment with CsA does not inhibit epidermal proliferation in vivo. So far, the 
question why keratinocytes contain cyclophilin remains unresolved. It is remotely possible 
that the release of cytokines from the epidermis might be modulated by systemic CsA 
treatment 
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Chapter VI 
GENERAL DISCUSSION 

6.1 Major conclusions 
In healthy, undamaged human epidermis, basal ODC activity is less than 1 pmol/min/mg 
protein. Following tape stripping, an at least 80-fold stimulation is reached at 8 h, 
followed by an abrupt decline to a level of about 10 pmol/min/mg protein, which 
remains constant for 36 h following stripping. This response does not differ between 
controls and psoriatic patients, which makes an etiological role of ODC in the 
pathogenesis of psoriasis unlikely. 
In the psoriatic lesion ODC shows an activity of about 5 pmol/min/mg protein and 
in this pathologic situation all basal cells are cycling.' So this ODC level has to be 
sufficient to provide polyamines for maximal DNA synthesis. Ki-67 (a monoclonal 
antibody that binds to a nuclear antigen expressed in cycling cells) starts to increase 32 
h after stripping and reaches a peak at 40 h,2 in parallel with the curve of the percentage 
cells in SG2M-phase.3 The first wave of DNA synthesis begins around 32 h after 
stripping: according to our induction curve a time point with almost twice as much ODC 
activity than is needed for maximal DNA synthesis. Therefore it is attractive to 
speculate that the ODC peak 8 h after stripping is not directly associated with DNA 
synthesis, but may have a role in the differentiation program. 
As we have seen in Chapter I, proliferation and differentiation are closely linked in 
epidermis and this is especially true for the synthesis of keratins, transglutaminase and 
involucrin. Following tape stripping, keratinocytes show changes in the pattern of 
keratin synthesis within 8.S h, i.e. the appearance of keratin 6 and 16 and a reduction of 
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synthesis of keratin l.3,4 Keratin 10 starts to decrease after 16 h.3 Alterations in the 
patterns of staining with anti-involucrin and antitransglutaminase are visible within 15 
h.4 Therefore it seems logical to search for an essential function of the abundance in 
polyamines at 8 h in these processes, an underestimated thought in the literature.5,s·7 
Providing an alternative substrate for transglutaminase8,9 may be an explanation, since 
this will result in a quick "first-aid" covering of the still viable, but unprotected 
epidermal cells... 
Proliferation is restricted to the stratum basale only and the events in the 
differentiation process mentioned above take place in the suprabasal layers. ODC is 
thought to be expressed in the stratum basale only (in normal epidermis and following 
injury, although even in situ hybridization techniques have not proven this with 
certainty.10·11·12 Do polyamines diffuse from the stratum basale into the suprabasal layers 
or are they also produced by the stratum spinosum and granulosum themselves? Hence 
many questions still have to be answered before the role of ODC in keratinocyte 
maturation will become completely clear. 
Measurement of the ODC peak 8 h after stripping still represents a practical 
approach to study epidermal proliferation, since the peak (i) indicates an exit from Go-
phase in at least cultured ЗТЗ-cells13 and other tissues in vivo,1415 (ii) parallels the 
dynamics of activation of PKC by TP A16 and (iii) permits comparison of possible 
inhibitory effects of drugs. 
Our conclusions that neither prostaglandins nor leukotrienes are essential for 
epidermal ODC induction in humans in vivo, imply that observations in humans are 
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difficult to extrapolate from rodent data, and other mechanisms have to play a role in the 
inhibition of ODC induction by corticosteroids. Further, epidermal ODC induction is not 
altered in patients receiving Non-Steroidal Anti-Inflammatory Drugs. 
In chapter IV it has become clear that the known ligands of the steroid hormone 
receptor superfamily (SHRS) that block epidermal ODC induction must be broadened to 
include the vitamin D3 derivative MC903 and estriol. Our finding that MC903 was not 
capable of reducing lesionai ODC levels, however, is probably due to a methodological 
problem. Instead of an at random designation of all biopsy sites at the beginning of the 
trial, those at the end of the trial were generally taken from small remaining psoriatic 
lesions at the periphery of the original plaque. The clinical relevance of our surprising 
finding with estriol, i.e. a pronounced inhibition of epidermal ODC induction in the 
range of a potent corticosteroid, will hopefully become clear in the near future. 
In the Introduction we asked the question whether ODC could be used as a marker 
enzyme to test (new) antipsoriatic drugs. The answer has to be "yes", with the proviso 
that failure to block epidermal ODC induction does not necessarily exclude antipsoriatic 
potential. UVB and dithranol (unpublished data) induce ODC themselves, coal tar and 
cyclosporin A do not influence ODC induction and several ligands of the SHRS are 
potent inhibitors of ODC induction. These in the first instance conflicting data may well 
be explained by a vicious circle between the epidermis and the immune system; both 
stimulate/induce each other and it does not matter where in the circle an antipsoriatic 
therapy interferes in this process. 
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6.2 Signal transduction pathways mediated by inflammatory stimuli: 
current concepts 
Combining the data described in this thesis with the facts that in the meantime have 
become available in the literature, gives the picture of the pathways involved in ODC 
induction as shown in Fig. 2, which differs from the pathway indicated in Fig. 6 of the 
Introduction. However, before explaining those routes in greater detail, the general 
overview will be enhanced by a re-evaluation of Fig. 2 in chapter I. In particular, it is now 
possible to suggest a mechanism for the "common pathway", regulating both proliferation, 
differentiation and inflammation after several kinds of "traumatizing " induction stimuli: 
the TGFoc autocrine loop (Fig. 1). 
TGFa 
other 
targets 
other 
targets 
[Ca-2+] 
ODC bradykinine 
Fig. 1 
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When epidermal cells are activated (for example by TGFa in an autocrine or paracrine 
fashion), this will finally result in secretion of TGFa by these cells themselves and this 
vicious circle is known as the TGFa autocrine loop.17 The loop is normally quiescent and 
becomes active only after an incoming "trauma" signal. This may be bradykinin in 
plasma,18 but other cytokines including TNFa, IFNy and IL8 have recently been shown to 
induce TGFa expression in organ cultures of human skin.'9 Several out-going signals 
further influence proliferation, inflammation and differentiation. If the loop gain is less 
than unity, the signal will eventually die out, and the skin will return to normal. If in the 
near future this rather hypothetical concept should prove to be correct, it would be logical 
to assume that psoriasis is characterized by an "intrinsic error" in the loop gain itself. 
Investigating the validity of this concept has just started in our laboratories. 
Our current view of the transduction pathway of epidermal ODC induction is given 
in Fig. 2. The steps between stimulation of the EGF-R and activation of PKC have 
remained similar, but the following events have changed as result of new experimental 
data (for a review, see the special issue of Trends in Biochemical Sciences, Volume 17 
No. 10, 1992, called 'Signal Transduction : Crosstalk'). In a simplified form, activated 
PKC stimulates the transcription factor AP-1, a c-jun/c-fos heterodimer,20 that induces 
ODC transcription.21 Activated AP-1 blocks the DNA-binding domain of the activated 
corticosteroid receptor (CS-R) and the reverse is also true: an explanation why 
corticosteroids reduce epidermal ODC induction.22 Whether the other members of the 
SHRS have a same mode of action remains to be proven, but seems logical according to 
our findings.23 The activated CS-R is a transcription factor for lipocortin (LC), that blocks 
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activity of PLA2. However, phosphorylation of LC by PKC liberates PLA2, hence the 
release of AA and its products will follow.24 This explains why PGs and LTs are closely 
linked to, although not essential in the pathway of epidermal ODC induction, as shown in 
chapter II and III. 
Fig. 2 
6.3 Relevance of ODC in the future 
"(...) Effective antipsoriatic agents (...) have also been found to reduce epidermal 
polyamine synthesis. Inhibition of polyamine synthesis may prevent growth in several 
experimental systems, and this inhibition is reversed by adding back polyamines. The 
inhibitor of polyamine synthesis, methylglyoxal-tó(guanylhydrazone) was also found to 
have a slight effect in controlling psoriatic lesions. (...) Further work is needed in this 
important area. (...)" [Camp RDR. Psoriasis. In: RH Champion, JL Burton, FJG Ebling 
118 
(eds.) Textbook of Dermatology (5й1 edition). Blackwell Sc Pubi, Oxford 1992; 1399-1400] 
"(...) the inhibition of polyamine production is and remains a feasible therapeutic approach 
in diverse areas. The reasons for the disappointing results in clinical cancer chemotherapy 
and the slow progress of the treatment of human hyperproliferative skin diseases with 
inhibitors of ODC (...) are merely technical ones. These include dosing of the drugs, 
cellular compensatory mechanisms triggered in response to polyamine depletion, galenic 
forms to be used topically, and selection of the right partner for combined regimens, just 
to mention a few. (...) What is the reason for the extraordinary sensitivity of trypanosomes 
(parasites) to difluoromethyl-ornithine (a direct ODC inhibitor) not only under 
experimental conditions, but also in clinical settings? A proper answer to this question 
may solve everything: Isn't a cancer cell also a parasite? (...)" [Jänne J, Alhonen-Hongisto 
L. Inhibitors of ornithine decarboxylase: biochemistry and applications. In: SI Hayashi 
(ed.) Ornithine decarboxylase: biology, enzymology and molecular genetics. Pergamon 
Press NY 1989; 77-78] 
According to these relatively recent quotations, the relevance of epidermal ODC activity to 
psoriasis remains clear in the future. It seems of interest (both from a dermatological and 
oncological point of view) to study the influence of gut-decontamination and food-intake 
on ODC induction in "non-vascularized" epidermis. Do alterations in polyamine-uptake 
explain inter- and intra-individual differences in the level of ODC induction in human 
skin? Does polyamine-uptake modify expression of hyperproliferative skin diseases? 
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Clinical and laboratory studies to elucidate these questions seem worthwhile. 
Looking at Figure I, ODC can be an indirect tool in verifying the mechanism of the 
TGFa loop (stimulation of cultured keratinocytes that have been arrested in G0-phase) and 
elucidating the pathways for 'on' switches of vital importance (bradykinin, TNFa, IL8, 
amphiregulin,25 etc.). Although, in fact, both require measurement of TGFa itself. 
The interpretations of our results with sphingosine, tannic acid and estriol will certainly 
improve when data regarding their influence on ODC induction in cultured keratinocytes 
become available. This applied work is then easily extended by screening specific 
inhibitors of the key-enzymes in the TGFa loop, such as serine/threonine kinase inhibitors, 
tyrosine kinase inhibitors and receptor-antagonizing oligopeptides. Studies on the efficacy 
of these inhibitors will provide the ultimate reality testing of the pathogenetic relevance of 
TGFa associated processes in psoriasis. Thus, ODC studies can provide first indications 
for potent anti-inflammatory, cytostatic or anti-psoriatic agents, which may become 
available in the future: Isn't a psoriatic cell also a parasite? 
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SUMMARY 
In the Introduction (chapter I) a description of epidermal proliferation, inflammation and 
differentiation is presented and the close relations between these processes are discussed. 
All three are disturbed in the skin disease psoriasis, in a way that looks very similar to 
the response to an acute trauma. Ornithine decarboxylase (ODC) is closely involved in 
DNA replication and has been extensively investigated in rodent skin, but human data 
regarding epidermal ODC induction pathways are scarce. Therefore, in this thesis 
stripping of the stratum corneum and irradiation with UV-B are used as models for 
standardized trauma and the level of ODC induction is used as a marker for epidermal 
proliferation in humans in vivo. 
Chapter II provides the basis for this thesis. This includes (I) a complete description of 
the methods used, (II) an ODC induction curve following epidermal stripping of healthy 
volunteers, (III) comparison of this curve with the ODC induction curve in psoriatic 
uninvolved skin and (IV) the influence of a topical corticosteroid (an indirect inhibitor 
of arachidonic acid) and oral indomethacin (a cyclooxygenase inhibitor) on this 
induction process. The results demonstrate an ODC peak after 8 h, no difference 
between healthy and psoriatic subjects, a marked inhibition by the topical corticosteroid, 
but no effect of oral indomethacin. 
In chapter III the influence of prostaglandins and leukotrienes is further investigated, 
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since cyclooxygenase- and/or lipoxygenase-inhibitors have been claimed to block ODC 
induction in rodent skin. Topical Elmetacin11 (a cyclooxygenase inhibitor) and topical 
Dignodolin11 (which inhibits both cyclooxygenase and lipoxygenase) failed to show any 
inhibitory effect on epidermal ODC induction following either tape stripping or UV-B 
irradiation. This chapter excludes a role for eicosanoids in induction of ODC in human 
epidermis and indicates the danger of extrapolating rodent data to the human situation. 
Chapter IV reports the effects of two previously uninvestigated ligands of the steroid 
hormone receptor superfamily on epidermal ODC induction, calcipotriol and estriol. 
Their inhibitory capacity proved to be in line with other members, namely 
corticosteroids and retinole acid. Speculations regarding these findings become attractive, 
since corticosteroids, retinoic acid and recently also calcipotriol (as shown in paragraph 
4.1) are all used as potent antipsoriatic drags. 
In chapter V the line of chapter IV is continued by asking whether ODC can be used as 
marker-enzyme to test (new) antipsoriatic therapies. Topical sphingosine (a protein 
kinase С inhibitor), isoquinoline (a component of the antipsoriatic agent coal tar), tannic 
acid (an inhibitor of ODC induction in mouse skin) and oral cyclosporin A (an 
immunosuppressive drug) were all tested for their capacity to block epidermal ODC 
induction and their efficacy in reducing the psoriatic plaque. Our results indicate that 
ODC can, indeed, be a useful marker, with the proviso that failure to block epidermal 
ODC induction does not necessarily exclude antipsoriatic potential. 
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Chapter VI reviews the major conclusions in the light of current concepts in signal 
transduction pathways. Two positive feedback loops are discussed. First, the vicious 
circle between the epidermis and the immune system results in a psoriatic plaque; both 
stimulate or induce each other, and an antipsoriatic drug may interfere with this cycle at 
various targets (chapters IV and V). Secondly, the epidermal TGFa autocrine loop may 
function as a common pathway, with input-signals from the epidermis and the immune 
system, and output-signals, controlling proliferation, inflammation and differentiation 
(i.e. ODC, as shown in chapters I and II). These findings support the hypothesis that 
psoriasis may be characterized by an "intrinsic error" in the TGFa loop gain. 
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SAMENVATTING (Dutch translation) 
In de Introductie (hoofdstuk I) worden epidermale proliferatie, inflammatie en 
differentiatie beschreven en wordt de hechte relatie tussen deze processen besproken. 
Alle drie verlopen gestoord in de huidziekte psoriasis en wel op een wijze die sterke 
overeenkomsten vertoont met de reactie op een acuut trauma. Ornithine decarboxylase 
(ODC) is nauw betrokken bij de DNA-verdubbeling en is uitgebreid onderzocht in de 
huid van dieren, maar menselijke gegevens over de epidermale ODC inductie cascade 
zijn schaars. Daarom worden in dit proefschrift strippen van het stratum corneum en 
bestraling met UV-B benut als modellen voor een gestandaardiseerd trauma en wordt het 
niveau van ODC inductie gebruikt als een kenmerk voor humane epidermale proliferatie 
in vivo. 
Hoofdstuk II levert de basis voor deze thesis. Dit omvat (I) een volledige beschrijving 
van de gebruikte methodologie, (II) een ODC inductie curve na epidermaal strippen van 
gezonde vrijwilligers, (III) een vergelijking van deze curve met de ODC inductie curve 
in de klinisch niet aangedane psoriatische huid en (IV) de invloed van een locaal 
corticosteroid (een indirecte remmer van arachidonzuur) en oraal indomethacine (een 
cyclo-oxygenase remmer) op dit inductieproces. De resultaten laten een ODC piek na 8 
uur zien, geen verschil tussen gezonde en psoriatische personen, een duidelijke remming 
door het locale corticosteroid, maar geen effect van oraal indomethacine. 
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In hoofdstuk III wordt de invloed van Prostaglandines en leukotriè'nes verder onderzocht, 
aangezien cyclo-oxygenase- en/of lipoxygenase-remmers de ODC inductie in de huid 
van muizen en ratten zouden blokkeren. Locaal Elmetacin11 (een cyclo-oxygenase 
remmer) en locaal Dignodolin11 (zowel een lipoxygenase- als cyclo-oxygenase-remmer) 
lieten absoluut geen blokkade zien van de epidermale ODC inductie, na tape strippen 
noch na UV-B bestraling. Dit hoofdstuk sluit een rol voor eicosanoïden in de ODC 
inductie in de menselijke huid uit en illustreert het gevaar van extrapoleren van dierlijke 
gegevens naar de humane situatie. 
Hoofdstuk IV rapporteert over de effecten van twee niet eerder onderzochte leden van 
de steroid hormoon receptor superfamilie op de epidermale ODC inductie, calcipotriol 
en estriol. Hun remmende eigenschappen bleken overeen te komen met twee andere 
leden, namelijk corticosteroiden en retinoïnezuur. Het is aantrekkelijk om over deze 
bevindingen te speculeren, aangezien corticosteroiden, retinoïnezuur en sinds kort 
eveneens calcipotriol (zoals wordt aangetoond in paragraaf 4.1) allen worden aangewend 
als krachtige antipsoriatische medicijnen. 
In hoofdstuk V wordt de lijn in hoofdstuk IV gecontinueerd door te vragen of ODC 
kan worden gebruikt als "marker"-enzym voor het testen van (nieuwe) antipsoriatische 
therapieën. Topisch sphingosine (een proteine kinase С remmer), isoquinoline (een 
grondstof in het antipsoriatische middel koolteer), tanninezuur (een remmer van de ODC 
inductie in muizehuid) en oraal cyclosporine A (een immunosuppressief geneesmiddel) 
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werden allemaal getest op hun vermogen om de epidermale ODC inductie te blokkeren 
en voor hun effectiviteit in het reduceren van de psoriatische laesie. De resultaten geven 
een positief antwoord op de vraag of ODC als "marker"-enzym kan worden benut, zij 
het met de opmerking dat falen in het remmen van de epidermale ODC inductie niet per 
sé een antipsoriatisch vermogen uitsluit. 
Hoofdstuk 6 bespreekt de voornaamste conclusies in het licht van de nieuwste inzichten 
in de cascades voor de overdracht van signalen. Twee positieve terugkoppelings-
kringlopen worden besproken. Ten eerste resulteert de vicieuze cirkel tussen de 
epidermis en het immuunsysteem in een psoriatische laesie; beide stimuleren c.q. 
induceren elkaar en een antipsoriatisch medicijn kan op verschillende plaatsen in deze 
cirkel aangrijpen (hoofdstuk IV en V). Ten tweede kan de epidermale autocriene TGFa 
kringloop als een algemene centrale cascade fungeren, met binnenkomende signalen uit 
de epidermis en het immuunsysteem en met uitgaande signalen die proliferatie, 
inflammatie en differentiatie reguleren (bijv. ODC, zoals beschreven in hoofdstuk I en 
II). Deze bevindingen ondersteunen de hypothese dat psoriasis veroorzaakt kan worden 
door een intrinsieke fout in de "terugkoppelingsfactor" van de TGFa kringloop. 
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